GENETIC AND EPIGENETIC MECHANISMS OF COMPLEX REPRODUCTIVE DISORDERS by Modi, Bhavi P
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2016 
GENETIC AND EPIGENETIC MECHANISMS OF COMPLEX 
REPRODUCTIVE DISORDERS 
Bhavi P. Modi 
Virginia Commonwealth University 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Female Urogenital Diseases and Pregnancy Complications Commons, Genetic Phenomena 
Commons, Genetic Processes Commons, and the Obstetrics and Gynecology Commons 
 
© The Author 
Downloaded from 
https://scholarscompass.vcu.edu/etd/4574 
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It 
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars 
Compass. For more information, please contact libcompass@vcu.edu. 
	© Bhavi P. Modi, 2016 
 
All Rights Reserved 
  
	GENETIC AND EPIGENETIC MECHANISMS OF COMPLEX REPRODUCTIVE 
DISORDERS 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
 
 
By 
 
 
BHAVI P. MODI 
Master of Science, Biotechnology, University of Mumbai, 2012 
 
 
 
 
 
 
 
 
 
 
 
Advisor: Jerome F. Strauss III, M.D., Ph.D. 
Dean of the School of Medicine 
Professor, Dept. of Obstetrics and Gynecology and Dept. of Human and Molecular 
Genetics 
 
 
 
 
 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
December 2016
	 ii	
Acknowledgement 
 
 
 
It is a pleasure to thank the many people who have made this dissertation possible and 
because of whom I will cherish my graduate experience forever.  
First and foremost, I would like to express my sincere gratitude to my advisor and 
mentor, Dr. Jerome F. Strauss for giving me the opportunity to work under his guidance. 
I appreciate all of the time and effort he has put in training me as an independent 
research scientist. He made sure I learnt as much as I could and widened my expertise 
beyond the limitations of graduate requirements. He will always be a positive research 
role model for me. 
I am sincerely grateful to the members of my graduate committee including Dr. 
John Nestler, Dr. Joyce Lloyd, Dr. Rita Shiang and Dr. Kellie Archer. Their individual 
expertise and willingness to invest time in my training have been a huge help. Together 
they ensured that I got a well-rounded graduate experience and will always be an 
inspiration to hold myself to high research standards.  
I would also like to express my appreciation to our collaborators, Dr. Jan M. 
McAllister, Dr. Roberto Romero, Dr. Timothy P. York, Dr. Laurel Pearson, Dr. Colleen 
Jackson-Cook, Dr. Scott Walsh and Sonya Washington for providing samples, helping 
with data and statistical analysis, providing their intellectual insight and feedback on the 
manuscripts that have resulted from this work.  
I am incredibly grateful for my work family – members of the Strauss Lab for 
being the best colleagues I could have asked for. Dr. Maria Teves and Dr. Eun Lee 
have taught me a lot that I know, have not only guided me with the science, but have 
also been amazing friends and confidants. It has been a pleasure working alongside all 
other past and current lab members and colleagues, especially DaShaunda Hillard.  
Pursuing a Ph.D. alone in a new country is difficult in more ways than I can 
express and it would have been impossible without the love and support of my family. I 
dedicate this thesis to my parents, Pinesh and Jasmina Modi, my sister Rashi, and my 
boyfriend, Nitish Nayak for being my strength and support system from miles away. 
They have always stood by my side, encouraged me in my lowest times and cheered 
the loudest with each achievement along the way. Their love and relentless faith in my 
capabilities has been the strongest motivation in completing this work. 
 
  
	 iii	
Table of Contents 
Page 
Acknowledgement…………………………………………………………………………… ii 
List of Tables…………………………………………………………………………………..vi 
List of Figures………………………………………………………………………………...vii 
List of Abbreviations…………………………………………………………………………ix 
Abstract………………………………………………………………………………………….x 
Chapters 
1. Introduction and Background………………………………………………………….1 
1.1. Introduction…………………………………………………………………...…1  
1.2. PCOS background……………………………………………………..………3 
1.3. PPROM background………………………………………………….……...12 
1.4. MiRNA regulation in PCOS and PPROM……………………………..…...17  
1.5. Thesis Outline……………………………………………………………..…..18  
2. Genetic mechanisms of DENND1A.V2 overexpression in PCOS theca cells..20  
2.1. Introduction…………………………………………………………………....21  
2.2. Materials and Methods………………………………………………...……..25 
2.3. Results………………………………………………………………………....28  
2.4. Discussion…………………………………………………………………..…35  
3. MiR-125a-3p targets DENND1A.V2 and contributes to the V2 mediated 
steroidogenic phenotype in PCOS theca cells…………………………………….36 
	 iv	
3.1. Introduction…………………………………………………………………….37  
3.2. Materials and Methods……………………………………………………….40 
3.3. Results…………………………………………………………………………44  
3.4. Discussion……………………………………………………………………..58  
4. Rare mutations and potentially damaging missense variants in genes 
encoding fibrillar collagens and proteins involved in their production are 
candidates for risk for preterm premature rupture of membranes…………….64  
4.1. Introduction…………………………………………………………………….65  
4.2. Materials and Methods……………………………………………………….68  
4.3. Results…………………………………………………………………………72  
4.4. Discussion……………………………………………………………………..79  
5. Expression patterns of the Chromosome 21 microRNA cluster (miR-99a, miR-
125b and let-7c) in chorioamniotic membranes…………………………………...84  
5.1. Introduction…………………………………………………………………….85 
5.2. Materials and Methods……………………………………………………….86 
5.3. Results…………………………………………………………………………92 
5.4. Discussion……………………………………………………………………104 
6. Perspectives and Future Directions………………………………………………..108  
6.1. Underlying themes…………………………………………………………..109 
6.2. Future Directions…………………………………………………………….112 
 
	 v	
Bibliography…………………………………………………………………………………121  
Appendix……………………………………………………………………………………..151 
Vita………………………………………………………………………………………….....164 
 
  
	 vi	
List of Tables 
Table 1.1: PCOS risk loci reported to date………………………………………………….11 
Table 2.1: WES analysis of the DENND1A gene…………………………………………..31  
Table 2.2: Intron 10 sequence variation…………………………………………………….34 
Table 3.1: Differentially expressed miRNAs in normal and PCOS theca cells………….46  
Table 3.2: MiRNAs targeting GWAS genes………………………………………………...47  
Table 3.3: Ingenuity Pathway Analysis of the PCOS risk loci reported to date…………49 
Table 4.1: Characteristics of the study population…………………………………………76 
Table 4.2: Variants identified in genes involved in ECM composition and synthesis…..77  
Table 4.3: Allele frequencies of the variants identified…………………………………….78 
Table 5.1: Pairwise comparisons of miRNA expression by tissue and location………...97 
Table 5.2: Pairwise Pearson’s correlation of log2 miRNA expression by location for 
amnion…………………………………………………………………………………………..98 
Table 5.3: Pairwise Pearson’s correlation of log2 miRNA expression by location for the 
choriodecidua…………………………………………………………………………………..98 
Table 5.4: Ingenuity pathway analysis of the genes targeted by hsa-miR-99a, hsa-miR-
125b, hsa-let-7c………………………………………………………………………………101 
  
	 vii	
List of Figures 
Page  
Figure 1.1: Normal vs. Polycystic Ovary……………………………………………………...6 
Figure 1.2: PCOS diagnostic criteria………………………………………………………….7 
Figure 1.3: Genetic Architecture of Birth Timing……………………………………………15 
Figure 2.1: The DENND1A gene…………………………………………………………….24  
Figure 2.2: Copy Number Analysis in the DENND1A gene……………………………….32  
Figure 2.3: 3’ end of the DENND1A gene and intron 20 sequence variants identified...33 
Figure 3.1: IPA network of miRNAs and PCOS candidate genes………………………..50  
Figure 3.2: Decreased miR-125a-3p and miR-130b-3p expression in PCOS theca 
cells……………………………………………………………………………………………...54 
Figure 3.3: Decreased miR-125a-3p expression is correlated with increased 
DENND1A.V2 expression…………………………………………………………………….55 
Figure 3.4: Decreased miRNA expression is correlated with increased DHEA 
accumulation…………………………………………………………………………………..56 
Figure 3.5: MiR-125a-3p overexpression in H295R cells down-regulates DENND1A.V2 
and CYP17 mRNA expression, but has no effect on V1 expression…………………….57 
Figure 5.1: Sites of tissue collection…………………………………………………………91  
Figure 5.2: MiRNA expression in amniocytes………………………………………………94 
Figure 5.3: MiRNA expression in fetal membranes………………………………………..95  
Figure 5.4: Comparison of miRNA expression by tissue and location…………………..96 
	 viii	
Figure 5.5: IPA network……………………………………………………………………...103 
Figure 6.1: A hypothetical model for DENND1A and other GWAS candidate loci in 
PCOS………………………………………………………………………………………….114 
Figure 6.2: DENND1A.V2 construct………………………………………………………..116 
  
	 ix	
List of Abbreviations 
AMH: anti-mullerian hormone 
CYP17A1: cytochrome P450, family 17, subfamily A, polypeptide 1  
C-21: Chromosome 21 
DENND1A: differentially expressed in normal and neoplastic cells domain containing 
protein 1A. 
DHEA: dehydroepiandrosterone 
GWAS: genome-wide association studies 
miRNA: microRNA 
PCOS: polycystic ovary syndrome 
PCR: polymerase chain reaction 
PPROM: preterm premature rupture of membranes  
PTB: preterm birth 
sPTB: spontaneous preterm birth  
SNP: single nucleotide polymorphism 
T21: Trisomy 21 
T2D(M): type II diabetes (mellitus) 
TBP: TATA Binding Protein  
WES: whole exome sequencing 
  
	 x	
Abstract 
 
 
 
GENETIC AND EPIGENETIC MECHANISMS OF COMPLEX REPRODUCTIVE 
DISORDERS 
 
 
By, Bhavi P. Modi, Ph.D. 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
 
 
Virginia Commonwealth University, 2016 
 
 
Major Director: Jerome F. Strauss III, M.D., Ph.D. 
Dean of the School of Medicine 
Professor, Dept. of Obstetrics and Gynecology; Dept. of Human and Molecular Genetics 
 
 
 
Common, complex disorders are usually polygenic, heterogeneous and multifactorial 
traits representing interactions between environmental, genetic and epigenetic factors. 
Next generation genomic technologies have uncovered risk factors for several complex 
traits. More often than not, contributions of these risk factors have been studied 
individually. The application of these technologies to the study of complex female 
reproductive traits has been challenging. This thesis explores the potential of genetic 
and epigenetic components contributing to a better understanding of the
	 xi	
biological pathways underlying disease risk in two specific female complex reproductive 
traits - polycystic ovary syndrome (PCOS) and preterm premature rupture of 
membranes (PPROM). After introducing the clinical context and the genetic architecture 
for each disorder, I describe individual projects that together aim at understanding the 
genetic and epigenetic regulation of genes associated with disease susceptibility. The 
PCOS projects focus on characterization of a gene, DENND1A, whose association to 
PCOS was first established by Genome Wide Association Studies (GWAS) and one of 
its isoforms – DENND1A.V2, is known to functionally contribute to the PCOS pathology 
via increased androgen production. This study showed that decreased miR-125a-3p 
expression is correlated to increased DENND1A.V2 and increased DHEA accumulation 
in PCOS theca cells. A common network of differentially regulated miRNAs identified in 
this study and known PCOS candidate loci was also identified. The studies on PPROM 
utilize a Whole Exome Sequencing approach to identify rare variants in fetal genes 
contributing to extracellular matrix composition and synthesis contributing to PPROM 
risk. The results suggest that fetal contribution to PPROM is polygenic and is driven by 
a significant genetic burden of potentially damaging rare variants in genes contributing 
to fetal membrane strength and integrity. Tissue and location specific expression 
patterns of the Chromosome 21 miRNA cluster (miR-99a, miR-125b, let-7c) in fetal 
membranes from term pregnancies with spontaneous rupture were investigated. Unique 
expression profiles for all three miRNAs between the rupture and non-rupture sites were 
identified. The miRNAs were also differentially expressed between trisomy 21 (T21) and 
euploid control amniocyte cultures. The results suggest that these miRNAs play 
	 xii	
potential roles in fetal membrane rupture and fetal membrane defects associated with 
T21. 
Keywords: Polycystic Ovary Syndrome, DENND1A, Preterm Premature Rupture of 
Membranes, microRNA.  
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Chapter 1: Introduction and Background 
 
 
 
1.1. Introduction 
The genetic architecture of complex genetic disorders is represented by interactions 
between environmental, genetic and epigenetic factors. In contrast with single gene 
Mendelian disorders, single genetic variants are insufficient to cause complex genetic 
disorders. Instead, multiple variants of low penetrance at multiple loci act synergistically 
to contribute to complex disease risk. While environmental factors can be modified, the 
genetic factors predisposing to disease risk remain stable and need to be determined. 
The approaches used to study complex disease genetics have evolved rapidly with the 
development of new genomic technologies – from family-based studies and linkage 
analysis, twin studies, candidate-gene studies, to population-based techniques using 
microarray and next-generation sequencing approaches such as Genome Wide 
Association Studies (GWAS) and Whole Exome Sequencing (WES) (1,2).  
Genetic contributions to female reproductive disorders and pregnancy complications 
have been established but the precise genetic etiology contributing to disease 
mechanism is not yet completely understood. These disorders typically manifest as 
heterogeneous and complex traits resulting from multiple genetic and environmental 
factors (3). The progress of genetic studies in these disorders has been slow as 
compared to other complex genetic disorders such as schizophrenia (4) and coronary 
artery disease (5). This thesis describes the studies designed and performed
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to understand the genetic and epigenetic mechanisms of complex reproductive 
disorders, with specific focus on polycystic ovary syndrome (PCOS) and preterm 
premature rupture of membranes (PPROM).  
Demonstrating direct causation in any complex genetic trait is almost always 
impossible, and as discussed in the sections below, it is even more challenging for 
disorders of female reproduction. The research approaches utilized to identify genetic 
variants should be aimed at gaining evidence that variants at least show a consistent 
correlation with gene expression or gene regulation that is highly correlated with the 
human trait originally assayed (6). Together, the two models present opportunities to 
study complex disease genetics using three broad approaches. The studies on PCOS 
(Chapter 2) essentially focus on the characterization of a trait (PCOS) - associated 
locus originally identified by GWAS, but whose association to PCOS has been securely 
implicated. The studies on PPROM (Chapter 4) utilize a WES approach to identify rare 
variants contributing to PPROM risk, focusing on variant prioritization for replication and 
follow up in genes with biological relevance to PPROM. In addition the role of miRNAs 
in epigenetic mechanisms of gene regulation in both PCOS (Chapter 3) and PPROM 
(Chapter 5) is investigated. 
The following sections describe the clinical overview, genetic architecture and the 
ongoing research and its limitations in both PCOS and PPROM followed by a brief 
chapter-wise thesis outline.  
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1.2. PCOS background  
1.2.1. Clinical Overview of PCOS 
PCOS is a common reproductive endocrinological disorder that affects 5% - 15% 
women of reproductive age and is the leading cause of female infertility worldwide (7,8). 
It is a multisystem, heterogeneous disorder characterized by a broad spectrum of 
reproductive, metabolic and endocrinological features. The typical ovarian morphology, 
which gives the disorder its name, consists of multiple, small, subcortical follicular cysts 
in bilaterally enlarged ovaries. (Figure 1.1) Other features include irregular periods 
(oligo/ amenorrhea), oligo/ anovulation, infertility, hyperandrogenism, hirsutism, acne, 
insulin resistance and weight-gain (9). PCOS women have higher prevalence rates of 
cardiovascular disease, Type 2 Diabetes Mellitus (T2DM) and metabolic syndrome, 
irrespective of their age and body mass index (10,11).  
PCOS is one of the most ill-defined endocrinological conditions with considerably 
debated diagnosis schemes and varying prevalence rates based on the diagnostic 
criteria applied (7). Three different classification systems have been used for PCOS 
diagnosis over the years – the National Institutes of Health (NIH) criteria (12), the 
Rotterdam criteria (13), and the Androgen Excess and PCOS Society criteria (14) 
(Figure 1.2). This shows that the existing diagnostic criteria are based on expert 
consensus of clinical findings as opposed to strong molecular evidence and these are 
limited to reproductive-aged women. Several symptoms, especially reproductive and 
some endocrine features improve over time, however associated metabolic dysfunction 
persists throughout a woman’s lifetime further adding to risk for cardiovascular disease. 
Recently, the use of serum Anti-Mullerian hormone (AMH) levels as a biomarker for 
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PCOS diagnosis has been considered (15,16). In addition, none of these criteria include 
other endocrinopathies and metabolic features that are commonly observed in PCOS 
patients such as abnormal glucose metabolism, insulin resistance, dyslipidemia, weight 
gain and obesity. Development of molecular diagnostic techniques for PCOS will aid in 
early diagnosis in adolescents and pre-pubertal girls as opposed to late symptomatic 
diagnosis or more invasive procedures such as trans-vaginal ultrasound, and this can 
help prevent complications through lifestyle choices when possible for e.g. by controlling 
diet, exercise etc. Thus, accurate and early diagnosis of PCOS is essential not only to 
prevent potentially life-long associated comorbidities, but to also reduce the healthcare 
related economic burden of PCOS. The US health care system spends around 4 billion 
dollars annually in diagnosis and treatment of the primary PCOS symptoms as well as 
associated morbidities in pre-menopausal women (17). The hidden costs of life-long 
sequelae resulting from a PCOS background are difficult to estimate. It is also important 
to note that male and female first-degree relatives of women with PCOS have increased 
risk of developing associated metabolic and endocrine conditions including 
hyperandrogenism, obesity, insulin-resistance and T2DM (18,19). This underlines the 
genetic complexity of PCOS and further stresses the need to identify candidate genes.   
Most consensus diagnostic schemes recommend the presence of hyperandrogenism 
(clinical or biochemical) a must for concluding a PCOS diagnosis. A cross-sectional 
case-control study suggested that hyperandrogenism is implicated in both the metabolic 
and reproductive morbidities of PCOS and maybe a common link between the two 
(9,20). Ovarian androgen production is increased in PCOS and studies show that 
ovarian theca cells from PCOS women secrete more androgen than theca from 
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regularly ovulating women (21,22). Thus, hyperandrogenism is considered to be the 
hallmark of PCOS, which is directly or indirectly, linked to several other PCOS 
symptoms and is central to understanding PCOS etiology.  
	 6	
 
 
 
Figure 1.1. Normal vs. Polycystic Ovary: Normal ovulation follows a sequential series 
of developmental events in the follicles resulting in release of mature egg (ovulation). In 
a polycystic ovary, follicular development is arrested, resulting in accumulation of 
multiple immature follicles (< 10 mm), which overtime, appear as multiple small, 
subcortical follicular cysts.  
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Figure 1.2: PCOS diagnostic criteria. Three commonly used PCOS diagnostic criteria 
are described. A PCOS diagnosis requires the exclusion of other diseases that may 
contribute to these clinical criteria used including 21-hydroxylase deficiency, Cushing’s 
syndrome, and hyperprolactinemia. 
NIH	Consensus	De6inition	(1990)		
Hyperandrogenism	
Anovulation	
Rotterdam	Convention	(2003)		(any	2	of	3)	Hyperandrogenism	(Clinical/	Biochemical)	
Oligo-	and/	or	Anovulation	
Polycystic	Ovaries	on	Ultrasound	
Androgen	Excess	and	PCOS	Society	(2006)	
Hirsutism	and/	or	
hyperandrogenism	
(Required)	
Oligo-ovulation		and/	or		Polycystic	Ovaries	
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1.2.2. Genetic architecture of PCOS 
Initial evidence for genetic predisposition in PCOS was based on familial clustering of 
cases (23). The disorder was first thought to follow an autosomal dominant mode of 
inheritance with variable penetrance (8). Association and linkage studies and numerous 
candidate gene studies, though largely unsuccessful in yielding statistically significant 
and replicable results, provided evidence that a number of genes are differentially 
expressed in PCOS, which lend support to a polygenic mode of inheritance as opposed 
to a single-gene Mendelian model. Now, it is well established that PCOS is a complex 
genetic disorder with multiple genetic and environmental factors interacting and 
contributing to disease pathology (24,25). Twin studies and family-based association 
studies carried out on a Dutch population including more than 1300 monozygotic twins 
and 1800 dizygotic twins/ singleton sisters of twins showed that genetic factors account 
for ~70% of heritability in PCOS (26). The clinical features used for PCOS diagnosis, 
including polycystic ovaries, hyperandrogenism as well as oligo-amenorrhea have 
hereditary components with characteristics suggestive of an autosomal dominant trait 
(26–29). Hyperandrogenism is shown to be the strongest heritable characteristic in 
families with multiple PCOS patients (24,30). Other features commonly found in 
association with PCOS including metabolic syndrome, T2DM and obesity are also 
heritable characteristics (10,31,32). Environmental factors that may contribute include 
intra-uterine factors such as prenatal nutrition and/ or androgen exposure, while major 
postnatal factors are related to a person’s lifestyle such as diet, exercise, abdominal fat 
and body mass index (8).  
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The genetic architecture of PCOS has been summarized by Rosenfield et al (8) – “At its 
simplest, this is a “two-hit” hypothesis that can be thought of because of a congenitally 
programmed predisposition (“first hit”) that becomes manifest upon exposure to a 
provocative environmental factor (“second hit”)”. The congenital “hit” consists mostly of 
genetic variants affecting hyperandrogenism or ovarian function but can also be 
acquired factors such as intra-uterine nutrition or androgen exposure in utero. The 
provocative “hits” are postnatal factors including obesity and insulin resistance that may 
be caused by T2DM related gene variants. 
 
1.2.3. DENND1A: From GWAS to molecular mechanisms 
Candidate gene association studies in PCOS were primarily focused on genes involved in 
folliculogenesis, steroidogenesis, insulin production and function. Owing to small sample 
sizes and resulting limited statistical power, most of them failed to yield statistically significant 
results that could be replicated (24,25,33). The first successful GWAS in PCOS was 
published in 2011 on a Han-Chinese population with a follow-up GWAS published in 2012 
(34,35). Subsequent GWAS on European populations have confirmed associations of some 
(as shown in Table 1.1) of the variants identified in the Han-Chinese GWAS to PCOS, and 
also identified additional candidate loci (36,37). Together, the four GWA studies have 
identified 22 candidate loci for PCOS (Table 1.1). Interestingly, association of the DENND1A 
gene locus (Chromosome 9: 9p33.3) to PCOS has been consistently replicated in several 
studies (38–40). In addition, association to related phenotypes including elevated serum 
glucose levels, insulin levels and body weight has been documented (41).   
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As described in greater detail in chapter 2 studies in theca cells from normal cycling women 
and women with PCOS provide evidence for functional association of increased expression 
of an alternatively spliced isoform of the DENND1A gene - DENND1A.V2 (V2) to PCOS. 
While showing potential for V2 to be utilized as a diagnostic and therapeutic target, this study 
does not determine the mechanisms of V2 overexpression in PCOS theca cells (42). The 
DENND1A SNPs (single nucleotide polymorphisms) - identified in Han Chinese GWAS – 
rs10818854, rs2479106, rs10986105 - are located in the intronic regions of the gene (34,35). 
The DENND1A signal reported (suggestive locus – rs10760321) in European population is 
intergenic and was not confirmed in follow-up samples (37).  
The genetic mechanisms contributing to V2 overexpression need to be studied. Moreover, 
the reported odds ratios of association of the gene with PCOS are low to modest, which 
suggests variations in DENND1A and the resultant functional consequences of V2 
overexpression alone cannot explain the heritability of PCOS. Considering PCOS is a 
polygenic disorder and the known functional significance of DENND1A in PCOS etiology, it is 
more likely that other genes, possibly in a common network with DENND1A contribute to 
PCOS pathophysiology.  
	 11	
 
Table 1.1. PCOS risk loci reported to date. Genetic variants associated with PCOS risk 
identified in Han Chinese (CHN) and European (EUR) populations are described. 
Locus Gene GWAS Index SNP 
Risk/ 
Other 
allele 
Discovery 
p-value 
Discovery 
population Ref 
2p16.3 FSHR 
rs2268361 T/C 9.89 x 10-13 CHN 35 
rs2349415 T/C 2.35 x 10-12 CHN 35 
2p16.3 LHCGR rs13405728 G/A 7.55 x 10-21 CHN 34 
2p21 THADA 
rs13429458 C/A 1.73 x 10-23 CHN 34 
rs12478601 T/C 3.48 x 10-23 CHN 34 
rs12468394 A/C 1.59 x 10-20 CHN 34 
rs7563201 G/A 3.3 x 10-10 EUR 36 
2q34 ERBB4 rs1351592 G/C 1.2 x 10-12 EUR 36 
5q31.1 RAD50 rs13164856 T/C 3.5 x 10-9 EUR 36 
8p23.1 GATA4/NEIL2 rs804279 A/T 8 x 10-10 EUR 37 
9q22.32 C9orf3 
rs4385527 A/G 5.87 x 10-9 CHN 35 
rs3802457 A/G 5.28 x 10-14 CHN 35 
rs10993397 C/T 4.6 x 10-13 EUR 37 
9q33.3 DENND1A 
rs2479106 G/A 8.12 x 10-19 CHN 34 
rs10818854 A/G 9.4 x 10-18 CHN 34 
rs10986105 C/A 6.9 x 10-15 CHN 34 
rs10760321 A/G 1.4 x 10-6 EUR 36 
11p14.1 KCNA4/FSHB rs11031006 G/A 1.9 x 10-8 EUR 37 
11q22.1 YAP1 
rs1894116 G/A 1.08 x 10-22 CHN 35 
rs11225154 A/G 7.6 x 10-11 EUR 36 
12q13.2 RAB5B/SUOX rs705702 G/A 8.64 x 10-26 CHN 35 
12q13.2 ERBB3 rs7312770 C/T 2.1 x 10-7 EUR 36 
12q14.3 HMGA2 rs2272046 C/A 1.95 x 10-21 CHN 35 
12q21.2 KRR1 rs1275468 C/T 1.9 x 10-8 EUR 24 
16q12.1 TOX3 rs4784165 G/ T 3.64 x 10-11 CHN 35 
17q12 ERBB2 rs7218361 A/G 9.6 x 10-7 EUR 36 
19p13.2 INSR rs2059807 G/A 1.09 x 10-8 CHN 35 
20q13.2 SUMO1P1/ ZNF217 rs6022786 A/G 1.83 x 10-9 CHN 35 
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1.3. PPROM Background  
1.3.1. Clinical Overview of PPROM 
In humans, the normal term gestational period for singleton pregnancies is 37 – 41 
weeks, with gestational age determined from the first day of the last menstrual period or 
early second trimester estimation for confirming gestational age (43). Maternal and fetal 
physiological changes at term promote uterine contractions and breakdown of fetal 
membranes (amnion and chorion) to facilitate parturition. Variety of factors can 
contribute to early initiation or changes in these pathways resulting in preterm birth 
(PTB), which is defined as birth prior to 37 weeks of gestation. PTB is the leading cause 
of neonatal mortality and infant morbidity occurring in ~12% of all pregnancies in the 
United States (44,45). Children who are born preterm have increased risks of several 
short and long-term health sequelae owing to systemic immaturity. Immediate health 
complications include respiratory distress (due to poorly developed lungs), 
intraventricular hemorrhage, jaundice, anemia and infection. Long-term health impacts 
can include intellectual and developmental disabilities, cerebral palsy, lung problems, 
vision and hearing loss. In addition, children who are born preterm also have an 
increased risk of adult-onset diseases such as obesity, diabetes and hypertension 
(www.marchofdimes.com/prematurebabies). Despite the advances in research, 
healthcare and increasing knowledge of risk factors leading to PTB, the rate of PTB in 
US has not decreased in the last few decades (46,47).  
There are two major proximate causes for PTB – spontaneous PTB (sPTB) with intact 
membranes and preterm premature rupture of membranes (PPROM). Preterm 
premature rupture of membranes (PPROM) is characterized by rupture of the fetal 
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membranes prior to the onset of labor before 37 weeks of gestation. It occurs in 2% - 
3% of all pregnancies and accounts for approximately 40% of all PTBs (48). PPROM 
occurs at higher frequencies among African-American women compared to other 
populations in the US and these population-specific disparities cannot be explained by 
socio-economic factors. Genetic variation and therefore gene-environment interactions 
are thought to be involved (49,50).  
Diagnosis of PPROM is made based on visual pooling of clear amniotic fluid in the 
cervix, confirmation of alkaline pH of the cervicovaginal discharge (amniotic fluid) which 
is typically done using a nitrazine (pH indicator) test and/ or a fern test, which is 
microscopic observation of ferning patterns of amniotic fluid on drying. Using these 
clinical signs have limitations in terms of accuracy as most of these tests become less 
accurate more than 1 hour after membrane rupture (51).  
Understanding the genetic factors contributing to PPROM risk can help us identify early 
on in pregnancy, which women have an increased risk for PPROM. This can help 
identify the healthcare management options to prevent PPROM (by controlling other risk 
factors) and to assure best possible perinatal outcomes.  
 
1.3.2. Genetic Architecture of PTB/ PPROM  
Genetic contribution to PTB was initially widely debated with suggestions that variations 
in PTB risk including population-specific differences can be attributed to socioeconomic 
(education, access to healthcare), behavioral (smoking, alcohol and drug use), and 
environmental factors (stress). However, more studies demonstrated that these factors 
do not completely account for the risk of PTB in families and even after controlling for 
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these factors, PTB risk (specifically PPROM) is greater among African-Americans 
(49,50). This indicated that genetic factors likely contribute to PTB risk. Supporting this 
were reports indicating increased frequency of PTB in mothers with prior history of PTB 
and correlations observed between mother-daughter, sister-sister relationships within 
the same families. This is true even for PPROM. (52,53). These correlation patterns can 
be explained by both genetic as well as environmental factors shared within families 
and indicate that PTB and its specific sub-phenotype PPROM are complex genetic 
disorders. However, determining the genetic architecture is difficult because in addition 
to the heterogeneous, multifactorial, complex genetic nature of the disorder, the 
involvement of not one, but two genomes has to be considered – maternal and fetal. 
The contribution of fetal genetic factors have been estimated to range from 11 – 35%, 
whereas the contribution of maternal genetic factors is in the range of 13 – 20% (54). 
Gene x environment interactions are considerably more challenging to understand in 
PTB as compared to other complex genetic disorders due to the interaction between the 
in utero environmental effects of the maternal genotype and the developmental effect of 
the fetal genotype.  
Environmental factors contributing to PTB risk include familial sources of variation that 
would, in theory, affect all births of the same mother such as socioeconomic status, 
stress, smoking, congenital maternal health problems, and also those environmental 
factors that are unique to individual pregnancies such as infections (Figure 1.3). 
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Figure 1.3. Genetic Architecture of Birth Timing. The complex genetic architecture of 
PPROM is influenced by both maternal and genetic factors. Maternal genetic factors 
influence the fetal genetic factors as well as the fetal environment in utero.  In addition, 
gene x environment interactions exist between maternal genetic factors and general 
maternal environment such as nutrition status, smoking and substance abuse and 
pregnancy specific maternal environment such as acquired infections during pregnancy.  
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1.3.3. Rare Variant Analysis in fetal collagen genes contributing to PPROM risk  
GWAS has had very limited success in identifying loci associated to PTB. Identified loci 
lose significance after testing for multiple corrections or are not reproducible in follow up 
studies. This can be attributed to several limitations in study design such as limited 
sample size, inadequate power, population heterogeneity and variations in definitions of 
PTB including the proximate cause of PTB used for each study, which makes replication 
of results more difficult. (46,55,56). It is important to recognize that different sub-
phenotypes of PTB (sPTB or PPROM) may result from different pathways, and can 
even have varying contributions of participating genomes (maternal vs. fetal) towards 
the genetic risk. The poor outcome from standard genetic approaches used to study 
PTB suggests that other methods need to be utilized to identify the genetic contribution 
to PTB. There have been no PTB GWAS focusing specifically on PPROM as the 
etiology leading to PTB. The majority of studies have focused on candidate genes in the 
maternal genome involved in inflammatory pathways such as Tumor Necrosis Factor-
alpha (TNFA), Toll-like receptor 4 (TLR4) and Caspase Recruiting Domain protein - 15 
(CARD15) (57,58). Despite evidence of fetal contribution to PPROM established by twin 
studies, not many studies have investigated variations in fetal genes contributing to 
PPROM (54,59). As suggested earlier, the pathways and genomes contributing to 
PPROM can be vastly different to those contributing to sPTB. This also has been 
suggested in a recent study investigating the pathway analysis of genetic factors 
associated with the two PTB subtypes (60). Moreover, all studies on PTB in general 
have focused on identifying common variants contributing to preterm birth risk. A study 
of rare variants contributing to birth timing has not been performed. As described in 
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Chapter 4, this thesis describes a unique approach towards identification of rare 
variants in the fetal genome in select genes that are known to contribute to fetal 
membrane structure and integrity.   
 
1.4. MicroRNA regulation in PCOS and PPROM  
GWAS and WES are approaches used to investigate alterations within the DNA 
sequence (common and/ or rare variants) contributing to disease association or disease 
risk. In contrast, epigenetic approaches are used in the study of complex genetic 
diseases to investigate heritable gene expression changes that occur without alterations 
of the underlying DNA sequences and contribute to disease mechanisms. Commonly 
studied epigenetic changes include DNA modifications such as methylation and histone 
modifications.  
MiRNAs are small (20 – 24 nucleotides), single-stranded, non-coding RNA molecules 
involved in post-transcriptional regulation of gene expression via translation inhibition or 
mRNA degradation (61,62). Since miRNAs induce gene expression changes without 
altering underlying DNA sequences, they contribute to epigenetic mechanisms of gene 
expression regulation. Normal ovarian function and normal parturition require a series of 
closely coordinated events that require tightly controlled gene regulation. Several 
investigators have studied and identified the role of miRNAs in regulating the normal 
functioning of these pathways including folliculogenesis, androgen regulation, 
contributing to preterm birth and preeclampsia (63–65). PCOS as well as PPROM are 
perturbations of the normal ovarian and parturition or birth timing pathways and this led 
	 18	
us to the hypothesis that differential miRNA expression patterns could contribute to the 
epigenetic landscape of disease mechanisms for these two disorders.  
In addition, the study of miRNAs in female reproductive disorders and adverse 
pregnancy outcomes is especially exciting because of accessibility of miRNAs in the 
serum, plasma, urine and saliva either as free circulating forms or encapsulated in 
vesicles, making them excellent non-invasive diagnostic and prognostic biomarkers of 
disease. This is particularly helpful in PCOS and PPROM where non-invasive 
accessibility of disease relevant organs and tissues is difficult or impossible, making 
diagnosis and following of disease progression extremely challenging.  
 
1.5. Thesis Outline   
Chapter 2 describes the genetic mechanisms for V2 overexpression in PCOS theca 
cells via WES analysis, copy number variation assessment and analysis of genetic 
variants in the intronic region where alternative splicing of DENND1A gene is thought to 
occur to produce V2. None of these mechanisms provide concrete evidence of 
contributing to V2 overexpression in PCOS, suggesting the potential role of miRNA 
regulation. 
In Chapter 3 the epigenetic mechanisms of miRNA contribution to PCOS etiology via 
miRNA regulation are studied. Using miRNA deep sequencing, the study shows 
evidence for differential microRNA expression in PCOS theca cells as compared to 
unaffected control theca cells. It describes the potential role of miR-125a-3p in 
regulating DENND1A.V2 gene expression and contributing to hyperandrogenism in the 
PCOS theca.  
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Chapter 4 describes a whole exome sequencing approach in African Americans to 
identify rare genetic variants in fetal genes encoding fibrillar collagen and enzymes and 
chaperone proteins involved in collagen synthesis contributing to increased risk for 
PPROM. The findings suggest that the fetal contribution to PPROM is polygenic, and 
driven by an increased burden of rare variants that may also contribute to the disparities 
in rates of preterm birth among African Americans. 
Chapter 5 investigates tissue and location specific expression patterns of three miRNAs 
(miR-99a, miR-125b and let-7c) derived from Chromosome 21 in chorioamniotic 
membranes from term pregnancies with spontaneous rupture. Results suggest the Chr 
– 21 derived miRNAs play a potential role in fetal membrane rupture and fetal 
membrane defects associated with Trisomy 21. 
Chapter 6 discusses the connecting themes underlying the dissertation work in 
Chapters 2 – 5 and comments on future directions.  
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Chapter 2: Genetic mechanisms of DENND1A.V2 overexpression in PCOS theca 
cells. 
Please note: Part of the material in this chapter has been published in   
i) McAllister JM, Modi B, Miller BA, Biegler J, Bruggeman R, Legro RS, Strauss 
JF 3rd. Overexpression of a DENND1A isoform produces a polycystic ovary 
syndrome theca phenotype. Proc Natl Acad Sci USA. 2014; 111(15): E1519-
27  
ii)  Tee MK Speek M, Legeza B, Modi B, Teves ME, McAllister JM, Strauss JF 
3rd, Miller WL. Alternative splicing of DENND1A, a PCOS candidate gene, 
generates variant 2. Mol Cell Endocrinol. 2016; 434: 25 – 35 
 
 
 
Abstract 
Identification of DENND1A as a PCOS candidate gene in Han Chinese and European 
Genome Wide Association Studies, replication in follow-up association studies and 
evidence for overexpression of one of the isoforms – DENND1A.V2 (V2) - in PCOS 
theca cells responsible for their steroidogenic phenotype, makes the gene the most 
potential key factor in the molecular pathogenesis of PCOS. In order to completely 
understand the functional significance of this gene and its contribution to PCOS, it is 
first important to elucidate the exact mechanism by which V2 is produced and
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overexpressed in PCOS theca cells. The present study indicates that V2 is produced by 
the exonization of intronic regions between exons 20 and 21 within the DENND1A gene. 
In addition, genetic mechanisms including coding/ splice site variations, copy number 
changes as well as intronic region variations were investigated and no evidence for their 
contribution to overexpression of V2 in PCOS theca cells was found.  
2.1. Introduction 
Polycystic Ovary Syndrome (PCOS) affects 5% - 15% women of reproductive age 
across different ethnicities (7,8). The disorder is associated with a typical ovarian 
morphology of multiple, small, subcortical follicular cysts in bilaterally enlarged ovaries, 
irregular periods (oligo/ amenorrhea), oligo/ anovulation, infertility, hyperandrogenism, 
insulin resistance and weight-gain (9). It is a heterogeneous disorder with a strong
evidence for a genetic component, either autosomal dominant or oligogenic/ polygenic 
(25,30). Incomplete penetrance, epigenetic modification, and environmental 
contributions have hindered attempts to clarify the underlying mode of inheritance. 
Numerous candidate gene association studies have been conducted, but few have 
yielded statistically significant associations that have been replicated. Genome wide 
association studies (GWAS) with large populations of Han Chinese individuals identified 
eleven PCOS candidate loci, including DENND1A (34,35). Additional studies in 
European populations confirmed the association of DENND1A with PCOS strongly 
supporting DENND1A as a PCOS candidate gene (Chapter 1, Table 1.1) (36–40). In 
addition, association to related phenotypes including elevated serum glucose levels, 
insulin levels and body weight has been documented (41).  
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The 18 human genes in the DENND family encode proteins that function as Rab-
specific GTPases involved in membrane trafficking. The DENND1A gene consists of 22 
exons and encodes the protein connecdenn 1, which has a clathrin-binding domain 
thought to facilitate endocytosis (66). DENND1A yields two principal transcripts: variant 
1 (V1), encodes a 1009 AA protein with three DENN (differentially expressed in normal 
and neoplastic cells) domains and a C-terminal proline-rich domain; variant 2 (V2), 
encodes a 559 AA protein that contains the three DENN domains, but lacks the proline-
rich domain, and includes a C-terminal 33 AA sequence that differs from V1 (Figure 
2.1). Recent work has directly implicated V2 in the pathophysiology of PCOS: V2 mRNA 
and protein were overexpressed in PCOS theca cells compared to unaffected control 
theca cells; over-expression of V2 in unaffected control theca cells increased the 
abundance of cytochrome P450, family 17, subfamily A, polypeptide 1 (CYP17A1) 
mRNA, augmented dehydroepiandrosterone (DHEA) production and increased the 
activity of transfected CYP11A1 and CYP17A1 promoter-reporter constructs; and siRNA 
knockdown of V2 in PCOS theca cells reversed the PCOS phenotype. In addition, V2 
mRNA was abundant in urinary exosomes of PCOS women but not normally-cycling 
women (42). These results suggest the diagnostic potential of V2. Especially, a 
diagnostic method based on urine exosomal RNA would have a great potential as non-
invasive and early diagnosis tool, which will be helpful for early detection in prepubertal 
adolescent females (67). However, in order to completely understand the functional 
significance of this gene and its contribution to PCOS and to better exploit its use as 
potential diagnostic tool, it is important to elucidate the exact mechanism by which V2 is 
produced and overexpressed in PCOS theca cells. The SNPs in DENND1A identified by 
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GWAS are located in introns, and lack apparent functions that would favor splicing of V2 
over V1.  
As suggested previously overexpression of V2 in PCOS suggests the contribution of 
gain-of-function variation (42). Thus, we sought to determine the mechanisms leading to 
production of V2 and its overexpression in PCOS by testing several possible 
mechanisms including examination of coding or splicing variants in the DENND1A gene, 
investigation of copy number variations in the DENND1A gene and sequencing of the 
intronic region that may explain alternative splicing of V1 and V2. 
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Figure 2.1. The DENND1A gene. 
The DENND1A gene is a member of a family of 18 genes, which encode for proteins 
containing DENN domains: domains that are differentially expressed in normal and 
neoplastic cells. DENND1A has a tripartite DENN domain consisting of upstream (u-
DENN), central / core DENN and a downstream (d-DENN) elements which are 
separated by linker sequences.  V1 encodes a full-length protein with 1009 amino acids 
consisting of all three DENN domains, a clathrin-binding domain and a C-terminal 
proline rich domain. V2 encodes a protein with 559 amino acids containing the three 
DENN domains and the clathrin-binding domain (not shown in the figure but is present 
downstream of the three DENN domains), but lacks the proline rich domain and has a 
unique 33 AA sequence that is not present in the full-length protein.  
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2.2. Materials and Methods 
2.2.1. Unaffected and PCOS theca cells: Human theca interna tissue was obtained 
from age-matched (38 – 40 years old), normal cycling women and women with PCOS 
undergoing hysterectomy, following informed consent under a protocol approved by the 
Institutional Review Board of The Pennsylvania State University College of Medicine, as 
previously described (68). All oophorectomies were performed during the luteal phase. 
The diagnosis of PCOS was made according to NIH consensus guidelines (9), which 
include hyperandrogenemia, oligoovulation, polycystic ovaries, and the exclusion of 21-
hydroxylase deficiency, Cushing’s syndrome, and hyperprolactinemia. All of the PCOS 
theca cell preparations studied came from ovaries of women with fewer than six menses 
per year and elevated serum total testosterone or bioavailable testosterone levels (42). 
Each of the PCOS ovaries contained multiple subcortical follicles of less than 10 mm in 
diameter.  The control (unaffected) theca cell preparations came from ovaries of fertile 
women with normal menstrual histories, menstrual cycles of 21-35 days, and no clinical 
signs of hyperandrogenism. Neither PCOS nor unaffected control subjects were 
receiving hormonal medications at the time of surgery.  Indications for surgery were 
dysfunctional uterine bleeding, endometrial cancer, and/or pelvic pain.  Theca cells 
were isolated and cultured as previously described (68). All experiments comparing 
PCOS and unaffected control theca were performed utilizing 4th-passage theca cells 
propagated from frozen stocks of second passage cells in media as described 
previously (68). The passage conditions and split ratios for all control and PCOS cells 
were identical.  
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2.2.2. WES Analysis of Control and PCOS Theca Cell DNA. Unaffected control (n = 
6) and PCOS (n = 6) genomic DNA samples were subjected to whole exome 
sequencing at 100 millions reads, at 100X coverage using the Agilent SureSelect 51M 
capture kit with Illumina HiSEq 2000 sequencing, in conjunction with BGI Americas. 
Sequence reads obtained were aligned to the reference genome (Human hg19) by BGI 
Americas. Variant calling and summary of data production was performed by BGI. 
Visualization of data and identification of called variants was done using the IGV 
(Integrative Genomic Viewer) software. Only those variants with IGV support numbers 
>15 (count of the uniquely mapped base) for the alternative allele were selected from 
the control unaffected and PCOS theca cell samples for further analysis. SNPs in 
DENND1A were identified and their alternative allele frequencies were calculated. 
2.2.3. CNV Analysis 
From WES data: The reads obtained from WES were used to call for CNV using two 
different platforms – Conifer and ExomeCNV, in conjunction with BGI Americas. 
CNV Assessment using qPCR: Genomic DNA samples from unaffected (n = 6) and 
PCOS (n = 8) theca cell cultures were all adjusted to a concentration of 5 ng/µl for CNV 
qPCR assays. Quantitative PCR analysis was performed using commercially available, 
predesigned TaqMan Copy Number Assays from Life Technologies targeting two 
different regions in the DENND1A gene – i) overlapping exon 2 – intron 2 boundary and 
ii) overlapping exon 20 – intron 20 boundary. RNAse P Copy Number Reference Assay 
was used as the endogenous control. QPCR assay and analysis was performed in 
quadruplicates following manufacturer’s protocols on an ABI 7900 HT Fast PCR 
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System. The raw data obtained from the qPCR assay was analyzed by the maximum 
likelihood method available in the Copy Caller v1.0 software (Applied Biosystems). 
2.2.4. Genomic DNA Sequencing  
Genomic DNA isolated from leukocytes (20 unaffected control and 20 PCOS) and theca 
cell cultures (8 unaffected control and 8 PCOS) was prepared using the “Wizard” 
genomic DNA purification kit (Promega), and initial direct sequencing was initiated with 
primers S1280 and AS1670. The region encompassing exons 20 to 20A was amplified 
using primers S1626 and AS3776 and the resulting 2.15 kb fragment was cloned into 
pSC-A-amp/kan vector. Between 7 and 9 individual clones were selected from each 
sample and sequenced with primers S1280 and AS1670. Original chromatograms were 
visually inspected to identify double peaks.  
2.2.5. Minigene construction and splicing analysis  
Please note: minigene construction and splicing analysis were performed by Dr. Walter 
Miller’s laboratory at the University of California, San Francisco. Detailed description of 
the methods and results can be found in the published version of the paper (69). Briefly, 
in order to determine what forms of RNA were produced from each variant identified in 
Table 2.2, the 2.15 Kb fragment (of the region encompassing exons 20 – 20A including 
the intronic region in between) from each sequence variant (from Table 2.2) was 
digested with PciI and BsrFI to produce a 1731 bp fragment, which was used to create 
minigene constructs in pcDNA3.1 vector using CMV promoter and a bGH polyA tail. The 
design retains sequences from exons 20, 20A and 21, and parts of intronic region 
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between 20 and 20A and 20A and 21. These constructs were individually transfected 
into steroidogenic human adrenal NCI-H295A cells. After transfection, RNA splicing was 
assessed by RT-PCR followed by electrophoresis in 2% agarose gels. To distinguish 
the splicing products arising from the minigene constructs vs. those endogenously 
expressed in NCI-H295A cells, we used the vector-specific primer for RT-PCR. 
2.2.6. Statistical Analysis 
The significance of the association of intron sequence variation with PCOS was 
assessed using Pearson’s Chi Square Test. (P < 0.05, was considered significant).  
2.3. Results 
2.3.1. Genetic variants in the DENND1A gene 
Data from WES performed on DNA obtained from unaffected control (n = 6) and PCOS 
(n = 6) theca cell cultures were investigated to identify functional genetic variants in the 
DENND1A gene. As shown in Table 2.1, only synonymous coding-sequence and 
intronic variants were identified. No missense, splice-site or nonsense variants that 
could contribute to alternative splicing of V2 were identified (42). 
2.3.2. Copy Number Variations in the DENND1A gene 
No copy number differences were found between unaffected control and PCOS theca 
cell DNA by examining copy number changes in the WES data (6 control, 6 PCOS) as 
well as by in vitro TaqMan Copy Number Assays (6 control, 8 PCOS). The qPCR results 
from the in vitro Copy Number Assays targeting two regions (exon 2 – intron 2; exon 20 
– intron 20) in the DENND1A gene are shown in Figure 2.2. 
2.3.3. DENND1A.V2 arises by exonization of sequences in intron 20 
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The NCBI database lists multiple DENND1A transcripts; V1 and V2 being the major 
ones (42,66). Examining the coding regions of the V1 and V2 mRNAs showed that they 
are identical through the end of exon 20 and then diverge. V1 continues with canonical 
exons 21 and 22 to yield a 1009 AA open reading frame, while V2 lacks the sequences 
encoded by exons 21 and 22 and has a different coding sequence that is responsible 
for a 559 AA open reading frame with a unique C-terminal 33 AA. Using this sequence 
in silico to probe the DENND1A gene, we found that the 33 AA C-terminus of V2 was 
generated by exonization of sequences located ~1.5 kb downstream from canonical 
exon 20 and 19.5 kb upstream from canonical exon 21 (Figure 2.3 A) Because this 
“exonic” or coded sequence was flanked by intronic region on 5’end but not the 3’end, 
(coding for a stop codon causing production of truncated isoform V2 with 559 AA), we 
named this exon, cryptic exon 20A.   
2.3.4. Intron 20 Sequence Variation 
To determine if there is genetic variation in intron 20 that might give rise to alternative 
splicing that might determine whether the DENND1A gene expresses mRNA encoding 
DENND1A V1 vs. V2, genomic DNA from human leukocytes obtained from blood 
collected from unaffected control (n = 20) women and women with PCOS (n = 19) as 
well as from theca cell cultures obtained from unaffected control women (n = 8) and 
women with PCOS (n = 9) was sequenced. Using primers S1626 and AS3776, we 
amplified a 2.15 kb region and then used primers S1280 and AS1670 (Figure 2.3 B) to 
sequence the PCR products. Sequencing identified a complex variable region 330 bp 
upstream from exon 20A with an extended dinucleotide TG repeats. Direct sequencing 
of this region in some genomic DNA samples yielded garbled sequence data, 
	 30	
suggesting the presence of multiple sequence variants. Therefore, we cloned the 2.15 
kb product and then sequenced multiple clones and identified different sequence 
variants (Figure 2.3 C). Among the 10 variants (variants 2 - 11) identified in genomic 
DNA from unaffected and PCOS women, none appeared to be overrepresented in 
PCOS women. Variants 2,4,9 and 11 were found in a limited number of samples from 
theca cells, and variants 2 and 4 were only found in samples from PCOS patients. We 
detected known SNPs including rs10739631, rs45480399, rs71490807, and 
rs10986007 (Figure 2.3 C) (69). The sequence variants were assessed and results are 
represented in Table 2.2. None of the variants were significantly associated to PCOS (P 
>0.05) 
2.3.5. Minigene Analysis of alternative splicing.  
Please note: minigene construction and splicing analysis were performed by Dr. Walter 
Miller’s laboratory at the University of California, San Francisco. Detailed description of 
the results can be found in the published version of the paper (69). Briefly, five splicing 
products were obtained arising from the minigene constructs created with each of the 
eleven variants shown in Figure 2.3 and Table 2.2. However, in two independent 
experiments with all constructs, none of these consistently favored splicing to favor the 
mRNA encoding the V2 isoform (69). 
Table 2.1. WES analysis of the DENND1A gene. DENND1A variants identified by 
WES are described along with the calculated alternate allele frequencies in the control 
(n = 6) and PCOS (n = 6) theca cell cultures. Alternate allele frequency in European 
American population (obtained from Exome 6500) was reported for comparison. (42) 
SNP 
Location 
(Chr 9) 
Function 
Ref 
Allele 
Alt allele  
Freq_Control 
Alt allele 
Freq_PCOS 
Alt allele 
Freq (EU)  
rs3739837 126143662 utr-3 G A (0.083) A (0.083) A (0.1109) 
rs2491348 126144746 Synonymous T C (1.0) C (1.0) T (0.0003) 
rs2808409 126144758 Synonymous T C (1.0) C(1.0) ABSENT 
rs2808411 126146197 Intron C G (1.0) G (1.0) C (0.082) 
rs10739631 126164562 Intron T C (1.0) C (1.0) ABSENT 
rs7872778 126201672 Intron G A (0.083) Absent ABSENT 
rs62581072 126201742 Intron G Absent A (0.083) ABSENT 
rs10739633 126202551 Intron A C (0.75) C (0.75) ABSENT 
rs3829851 126219706 Synonymous A G (0.083) Absent G (0.055) 
snp4115 126219742 Intron C Absent T (0.083) ABSENT 
snp3842 126220063 Intron G Absent T (0.083) ABSENT 
rs61736953 126220114 Synonymous C T (0.083) T (0.166) T(0.0884) 
rs12377595 126439100 Intron T G (0.166) G (0.33) G (0.2490) 
rs9785285 126520068 Synonymous T C (0.33) C (0.166) C (0.2123) 
rs41274356 126531724 Intron T C (0.083) Absent C (0.0239) 
rs1778890 126531755 Intron T C (0.33) C (0.166) C (0.2148) 
snp3895 126554844 Intron A Absent G (0.083) ABSENT 
rs670028 126641091 Intron A G (0.25) Absent ABSENT 
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Figure 2.2. Copy Number Analysis in the DENND1A gene. Results from TaqMan 
Copy Number qPCR assays for regions overlapping exon 2 – intron 2 (2.2 A) and exon 
20 – intron 20 (2.2 B) were analyzed in CopyCaller software and no copy number 
differences between control (n = 6) and PCOS (n = 8) theca cells were observed.  
 
	 33	
 
 
 
Figure 2.3. Diagram of the 3’ end of the DENND1A gene and intron 20 sequence 
variants identified. A. Scale diagram of ~20 kb spanning DENND1A exons 20 and 21; 
bases are numbered with the first base of exon 20 (Chr 9: 126145934), designated as 
base 1; exons are shown as boxes. B. Magnified diagram of the region between exons 
20 and 20A; the hypervariable region between the vertical dotted lines was identified by 
sequencing PCR products generated with primers S1626 and AS3776. C. Sequence 
variants in the hypervariable region with variant 1 depicting the WT sequence. Known 
SNPs in this region are highlighted: green, rs10739631; cyan, rs45480399; purple, 
rs71490807; grey, rs10986007. Newly identified variants at chr 9: 126164525 - 
126164521 are highlighted in yellow. (69) 
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Table 2.2. Intron 20 Sequence Variation. The intronic region between exons 20 and 
20A was assessed in the genomic DNA from human leukocytes obtained from blood 
collected from unaffected control (n = 20) women and women with PCOS (n = 19) as 
well as from theca cell cultures obtained from unaffected control women (n = 8) and 
women with PCOS (n = 9). The number of clones carrying each variant sequence 
(shown in Figure 2.3 C) in normal and PCOS samples and the average number of 
clones identified per sample for each variant are described. 
Variant No.	of	Clones	with	Variant	 Avg.	No.	of	Clones	with	Variant	per	sample	
Control PCOS Control PCOS 
1 65 42 3 2 
2 0 2 NA 1 
3 4 4 1 1 
4 0 2 NA 1 
5 18 20 3 2 
6 9 23 3 2 
7 18 28 2 2 
8 6 2 1 1 
9 2 2 2 2 
10 3 0 2 NA 
11 1 0 1 NA 
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2.4. Discussion 
Considering the established association between DENND1A and PCOS based on 
genetic association studies (34–39), genotype-phenotype correlation studies (40,41), in 
vitro functional studies (70) and its potential diagnostic and therapeutic applications 
(67), it was first important to understand the mechanism of V2 production and 
overexpression in PCOS theca cells. We report that the V2 isoform of the DENND1A 
gene is produced by exonization of sequences in intron 20, which generates a unique 
exon 20A, encoding the C-terminus of V2 (69). 
This is a comprehensive study investigating several possible genetic mechanisms for 
V2 overexpression in PCOS theca cells including sequencing analysis for coding region 
and splice-site variants, copy number analysis, analysis of the intronic region between 
exon 20 (present in both V1 and V2) and cryptic exon 20A (present in only V2). As 
shown in the results none of these mechanisms appear to contribute to increased V2 
expression in PCOS theca. The WES results are consistent with another study reporting 
no changes in DENND1A exons or splice junctions in PCOS (71).  
Genetic variation in the intronic region between exons 20 and 20A was identified. 
However, when each of these sequence variants was tested in a mini gene system, 
none of them consistently favored mRNA splicing to produce V2 instead of V1. Thus 
increased V2 expression in PCOS theca cells does not appear to result from genomic 
sequence variation in intron 20.  
It is important to note that though none of the genetic mechanisms we investigated, 
seemed to contribute to the observed V2 overexpression in PCOS theca cells, there 
maybe other potential genetic mechanisms including promoter region variants, variants 
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affecting mRNA stability (positively or negatively) in both DENND1A isoforms and 
epigenetic mechanisms including DNA methylations, histone modifications and miRNA 
regulation. Further investigation of these mechanisms contributing to V2 overexpression 
in PCOS theca cells is warranted. 
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Chapter 3: MiR-125a-3p targets DENND1A.V2 and contributes to the V2 mediated 
steroidogenic phenotype in PCOS theca cells 
 
 
Abstract  
Polycystic ovary syndrome (PCOS) is a multisystem disorder with a complex 
pathophysiology. Several microRNAs (miRNAs), small, non-coding post-transcriptional 
gene regulators, are known to be differentially expressed in granulosa cells, follicular 
fluid, ovarian stroma, and in the circulation of women with PCOS. However, there are no 
reports on miRNA expression and target gene analysis in control and PCOS theca cells. 
Understanding gene expression and its regulation in theca cells may represent a key to 
understanding the hyperandrogenemia characteristic of PCOS. The previously reported 
altered transcriptome profiles in PCOS theca cells could be explained, at least in part, 
by miRNA regulation. In the present study, we identified 18 miRNAs, which are 
differentially expressed in PCOS theca cells, some of which are predicted to target 
PCOS candidate genes identified by Genome Wide Association Studies. Using 
Ingenuity pathway analysis, we identified a common network with ~45% of the 
differentially expressed miRNAs identified in this study, and 73% of the PCOS 
candidate genes. In addition, miR-125a-3p, which was predicted to target DENND1A, 
one of the PCOS candidate genes, was shown to have specific interaction for the 
DENND1A.V2 isoform known to have a functional role in PCOS theca cell 
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steroidogenesis via correlation expression and mimic studies. In addition, miR-125a-3p 
expression was also negatively correlated to DHEA accumulation and overexpression of 
miR-125a-3p mimic also downregulated CYP17 mRNA expression. Our findings 
suggest an epigenetic mechanism of V2 overexpression in PCOS theca cells via miR-
125a-3p and suggest that the PCOS candidate genes derived from GWAS are part of a 
complex network regulated by miRNAs.  
 
3.1. Introduction   
Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects 5% - 
7% women worldwide. The disorder is heterogeneous, characterized by a broad 
spectrum of reproductive, metabolic and endocrinological features including 
hyperandrogenism, anovulation, infertility, and presence of multiple small subcortical 
follicular cysts embedded in bilaterally enlarged ovaries (20,28,72,73). Other 
endocrinopathies and metabolic features are commonly observed in PCOS patients 
including abnormal glucose metabolism, insulin resistance, dyslipidemia and obesity. 
PCOS women are known to have higher prevalence rates of type 2 diabetes (T2D), 
metabolic syndrome and cardiovascular disease (10,72). Most consensus diagnostic 
schemes recommend the presence of hyperandrogenism (clinical or biochemical) as an 
essential characteristic for reaching a PCOS diagnosis, and it is considered to be the 
hallmark of PCOS. A cross-sectional case-control study suggested that 
hyperandrogenism is implicated in both the metabolic and reproductive morbidities of 
PCOS, and maybe a common link between the two (9,20). Ovarian androgen 
production is increased in PCOS and studies show that ovarian theca cells from PCOS 
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women secrete more androgen than theca cells from regularly ovulating women 
(21,22,74–76). Thus, understanding gene expression and its regulation in theca cells is 
central to understanding PCOS pathophysiology, or at least hyperandrogenism 
associated with PCOS. Wood et al. (77,78) have shown that PCOS theca cells have a 
characteristic molecular signature as compared to normal theca cells. Although these 
results revealed altered gene expression in PCOS theca as compared to normal theca 
cells, it is not yet known whether the altered expression profile is the result of 
transcriptional or post-transcriptional regulatory mechanisms. 
MicroRNAs (miRNAs) are small (20-24 nucleotides) single-stranded, noncoding, 
regulatory RNA molecules. They are involved in post-transcriptional regulation of gene 
expression either by complimentary binding to the 3’ untranslated region of their target 
mRNA, thereby inhibiting translation or inducing mRNA degradation (61,62). The post-
transcriptional mechanism operationalized for down regulation of gene expression 
depends upon the binding target sequence. Messenger RNA degradation occurs in 
case of complete or near complete complementarity between miRNA and the target, 
while repression or inhibition of translation occurs if there is not sufficient 
complementarity for cleavage (62). Although not much is known about the roles of 
miRNAs in PCOS pathophysiology, there have been studies providing evidence of 
differential miRNA expression in the ovarian stroma, follicular fluid and granulosa cells 
of women with PCOS (63,79–81). Metformin, an insulin-sensitizing drug, which is used 
as a treatment to lower insulin and androgen levels and initiate ovulation in women with 
PCOS, changes global miRNA expression patterns (82). MicroRNAs are also reported 
to be stably expressed in encapsulated vesicles or free-circulating in the serum, plasma, 
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urine and saliva, making them potential non-invasive biomarkers for PCOS diagnosis 
(63).  
Several genome-wide association studies (GWAS) have identified loci significantly 
associated with PCOS. In a two-part study, GWAS on Han-Chinese populations 
identified 11 candidate loci (34,35).  Subsequent GWAS on European populations 
confirmed associations of some of the Han-Chinese GWAS to PCOS, and also 
identified additional candidate loci (36,37). Together, the 4 GWA studies have identified 
22 candidate loci for PCOS (Table 1.1, chapter 1), including DENND1A. Although some 
of these loci consist of plausible PCOS candidate genes, the molecular mechanisms by 
which most of the identified loci contribute to PCOS is not clearly understood. We 
demonstrated that the total mRNA transcript as well as a splice variant of DENND1A, 
DENND1A.V2, is increased in PCOS theca cells, with no change in the DENND1A.V1 
(full-length isoform) transcript expression (70). Forced expression of DENND1A.V2 in 
normal theca cells increased androgen production, whereas knockdown of 
DENND1A.V2 expression in PCOS theca cells reduced androgen synthesis, implicating 
DENND1A.V2 in the regulation of steroidogenesis and the PCOS phenotype (70). The 
mechanisms underlying the increased DENND1A.V2 expression in PCOS theca cells, 
as well as their altered transciptome signature in PCOS, remain to be elucidated.  One 
possibility is that these alterations result, in part, from differential expression of miRNAs.  
However, a detailed study of miRNA expression and target gene analysis has not been 
performed in theca cells.  
In the present study, miRNA expression profiles of human theca cell cultures, 
established from women with PCOS and without the disease were determined using 
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next generation sequencing. Target gene analysis of the differentially expressed 
miRNAs was focused on PCOS candidate genes identified by GWAS (34–37). Pathway 
and Network analyses (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity) were 
performed on the differentially expressed miRNAs between normal and PCOS theca 
cells identified in this study and the established GWAS candidate genes to identify a 
common network that may be involved in PCOS pathophysiology. Expression patterns 
of select miRNAs and target genes in the common network were validated by 
quantitative real-time PCR and associations of differential expression patterns (of both 
miRNAs and target genes) with androgen biosynthesis were investigated. 
 
3.2. Materials and Methods  
3.2.1 Cell culture: Human theca interna tissue was obtained from age-matched, normal 
cycling women (n = 6) and women with PCOS (n = 5) undergoing hysterectomy, 
following informed consent under a protocol approved by the Institutional Review Board 
of The Pennsylvania State University College of Medicine as previously described (68). 
Isolation of theca cells and theca cell cultures was done as described in Chapter 2. All 
theca cell cultures used for the following experiments were treated with and without 
20mM forskolin for 16 hours. Refer to Appendix, Table A.3.1 for details about samples 
used for different assays performed. 
H295R cells were obtained from ATCC and were cultured according to ATCC 
recommended culture conditions.  
3.2.2. MicroRNA Discovery Sequencing: MicroRNA discovery sequencing was 
performed using the Illumina technology (by LC Sciences, www.lcsciences.com) on 
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theca cell RNA from normal cycling women (n = 4) and women with PCOS (n = 4) each 
treated with (F) and without (C) forskolin. Total RNA was extracted using TRIzol 
reagents.  Small RNA library prep, cDNA deep sequencing and initial data analysis 
including alignment of raw reads to miRbase (v17) and normalization of count data was 
performed by LC Sciences. The log2 normalized expression levels for each miRNA were 
used for statistical analyses after filtering for human miRNAs.  
3.2.3. Target identification and Pathway analysis: The miRNA target prediction filter 
in Qiagen’s Ingenuity® Pathway Analysis tool (IPA®, QIAGEN Redwood City, 
www.qiagen.com/ingenuity) was used to identify potential target genes for the 18 
miRNAs that were differentially expressed between PCOS and normal theca cells (FDR 
< 0.05). MicroRNA-target gene relationships having a confidence level of 
“Experimentally Observed” or “High-Predicted” were considered. Pathway and network 
analyses were also performed in IPA.  
3.2.4. Quantitative RT-PCR based analysis of miRNA expression: Expression 
patterns of select miRNAs were validated in vitro using the TaqMan MicroRNA Assays 
(Life Technologies) following the manufacturer’s instructions. For the miRNA-qPCR 
assays, total RNA was extracted from the established theca cell cultures (Normal: n = 5 
and PCOS: n= 4; treated with and without forskolin) using miRVana miRNA isolation kit 
(Ambion, Life Technologies) following manufacturer’s protocol.  Briefly, 10 ng RNA was 
reverse transcribed using the target (miRNA) specific stem-loop RT primer and the 
TaqMan MicroRNA reverse transcription kit. The cDNA was then amplified by real-time 
qRT-PCR using target specific TaqMan primer-probe mix. The qRT-PCR was 
performed in triplicates per sample. Different small RNAs (RNU48, RNU43 and miR-16) 
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were tested for consistent expression between PCOS and unaffected control theca cell 
samples and RNU48 was selected for normalization of the qRT-PCR expression data. 
The mean expression value for each miRNA was divided by the mean RNU48 
expression value to normalize each sample. 
3.2.5. Quantitative RT-PCR based analysis of DENND1A.V1, DENND1A.V2 and 
CYP17 expression.  Quantitation of DENND1A.V1, DENND1A.V2 and CYP17 mRNA 
abundance was determined using the Single Step Brilliant III Ultra Fast SYBR qRT-PCR 
Reagents (Agilent) using 50-100 ng total RNA/tube, and 200nM final concentration of 
each forward and reverse primers, and 100nM probe. The gene specific one step PCR 
was carried out in duplicate for each mRNA sample and for a series of dilutions in an 
Mx3000p Thermocycler system (Stratagene) according to manufacturers instructions for 
this instrument as previously described (70). The primer and probe sets utilized were 
previously described (70). TATA Binding Protein (TBP) mRNA was used for 
normalization based on our previous studies (70). The mean expression value for each 
mRNA was divided by the mean TBP expression value to normalize each sample. 
3.2.6. Quantitation of Dehydroepiandrosterone (DHEA): ELISA for DHEA was 
performed on cell culture media without organic solvent extraction using kits from DRG 
International, Inc.  (Springfield, NJ) as described by the manufacturer’s protocol, and 
normalized by cell count.  
3.2.7. Mimic studies: H295R cells were transfected with miRVana hsa-miR-125a-3p 
mimic and negative control-1 mimic (Life Technologies) at a concentration of 75 nM 
using RNAiMAX transfection reagents and the manufacturer’s protocol. Cells were 
harvested 48 hours post transfection and total RNA was extracted using miRVana 
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miRNA isolation kit (Ambion Life Technologies) following the manufacturer’s protocol. 
V1, V2 and CYP17 mRNA qPCRs were performed on control and miR-125a mimic 
transfected RNA as described in section 3.2.5. 
3.2.8. Statistical analysis: For miRNA discovery sequencing analysis, for each miRNA, 
a one-way analysis of variance (ANOVA) model was fit to the log2 normalized 
expression levels to identify miRNAs differentially expressed among the four groups - 
Normal Untreated Control (Normal-C), Normal Forskolin Treated (Normal-F), PCOS 
Untreated Control (PCOS-C) and PCOS Forskolin Treated (PCOS-F). After fitting the 
ANOVA models for each miRNA, linear contrasts were used to test for differences 
between the following group comparisons: Normal-C vs. Normal-F; PCOS-C vs. PCOS-
F; Normal-C vs. PCOS-C; Normal-F vs. PCOS-F and Untreated (Normal-C and PCOS-
C) vs. Treated (Normal-F and PCOS-F). Meta-analysis was performed on miRNAs 
common between and having significant P < 0.05 in both group comparisons; Normal-C 
vs. PCOS-C, and Normal-F vs. PCOS-F.  Their individual P values were combined 
using Fisher’s method (83) for combining P values to get an overall comparison of 
miRNA expression between PCOS and normal theca cells. Subsequently, the combined 
P values were used to obtain the false discovery rate (FDR) using the Benjamini and 
Hochberg method (84). MicroRNAs having a statistically significant expression 
difference between both pair-wise comparisons (Normal-C vs. PCOS-C and PCOS-F 
vs. PCOS-F), a meta-analysis combined P < 0.05 and FDR < 0.05 were considered 
significant. All statistical analyses were performed using R (85). 
For the miRNA qRT-PCR assays, two sample t-tests were performed to test for 
differences between groups Normal-C vs. PCOS-C and Normal-F vs. PCOS-F. The P 
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values thus obtained were combined using Fisher’s method (83) and combined P < 0.05 
were considered statistically significant. Each miRNA specific cDNA was run in 
triplicates for the qRT-PCR assays.  
The results from mRNA qRT-PCR (DENND1A.V1 and DENND1A.V2) and steroid 
(DHEA) were collected from individual patients and ANOVA was performed to test for 
differences. P values were determined by the Bonferroni method for multiple 
comparisons. Data are presented and described in the text as the mean ± SEM 
performed triplicate and were prepared using Prism 5.0c (GraphPad Software, San 
Diego, CA).  
Spearman’s nonparametric correlation coefficient (ρ) was calculated to estimate the 
degree of correlation between all pairwise comparisons. (ρ was considered significant 
when P < 0.05). Please note that all samples treated with (F) and without (C) forskolin 
were considered together for the statistical analysis, giving a total of 10 unaffected 
control and 8 PCOS samples for Spearman’s correlation testing. Performing statistical 
tests for treated and untreated samples individually gave insignificant results owing to 
small sample size (n = 5 control unaffected; n = 4 PCOS samples) 
 
3.3. Results  
3.3.1. PCOS theca cells have differential miRNA expression as compared to 
Normal theca cells: A total of 1,823 miRNAs were identified from deep sequencing. 
After meta-analysis of the Normal-C vs. PCOS-C and Normal-F vs. PCOS-F pairwise 
comparisons, 18 miRNAs were found to be significantly differentially expressed 
between normal and PCOS theca cells (Fisher’s combined P < 0.05) with a FDR < 0.05 
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(Table 3.1). Of these 18 miRNAs, 13 miRNAs had increased expression and 5 miRNAs 
had decreased expression in PCOS theca cells as compared to unaffected control 
theca cells.  
3.3.2. Differentially expressed miRNAs in PCOS theca are predicted to target 
known PCOS candidate genes: The 18 miRNAs listed in Table 3.1 were used for 
bioinformatics analysis including target prediction and pathway analysis in IPA as 
described below. The miRNA target prediction filter in IPA was used to identify the 
validated and predicted target genes of the differentially expressed miRNAs (the 
miRNA-target gene relationships with IPA described confidence level of “Experimentally 
Observed” and “High-Predicted”) and a total of 6443 such interactions were identified. 
Interestingly 6 of the 18 miRNAs described in Table 3.1, were predicted to target 
(confidence level = High Predicted) 12 of 22 PCOS GWAS candidate genes identified in 
Han-Chinese (34,35) and European populations (36,37) and described in Table 1.1 
(Chapter 1). The predicted miRNA-GWAS gene interactions are shown in Table 3.2.  
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Table 3.1. Differentially expressed miRNAs in unaffected control and PCOS theca 
cells.  Using MicroRNA Discovery Sequencing, 18 miRNAs were differentially 
expressed between unaffected control vs. PCOS theca cells, 13 of which were 
upregulated and 5 were down-regulated in PCOS theca cells compared to normal. 
(Fisher’s combined P value < 0.05 and FDR < 0.05 considered significant) 
ID 
(hsa) 
PCOS/ 
Control 
(C) 
P value 
PCOS vs. 
Control 
(C) 
PCOS/ 
Control 
(F) 
P value 
PCOS vs. 
Control 
(F) 
meta 
P value 
meta 
FDR 
miR-501-3p 6.31 2.13E-06 5.56 5.20E-06 2.90E-10 5.29E-07 
miR-100-5p 4.89 4.74E-06 3.90 2.83E-05 3.19E-09 2.43E-06 
miR-409-5p 9.27 4.66E-06 6.51 3.65E-05 4.00E-09 2.43E-06 
miR-125a-3p 0.69 9.19E-06 0.76 1.17E-04 2.32E-08 1.06E-05 
miR-1271-5p 7.44 8.83E-05 5.61 3.70E-04 5.95E-07 2.17E-04 
miR-1301-3p 2.70 1.04E-03 3.08 2.87E-04 4.79E-06 1.45E-03 
miR-130b-3p 0.61 3.63E-04 0.72 6.70E-03 3.39E-05 8.23E-03 
miR-99b-5p 2.79 7.42E-04 2.37 3.51E-03 3.61E-05 8.23E-03 
miR-127-3p 2.15 1.72E-04 1.42 2.86E-02 6.45E-05 1.31E-02 
miR-148b-5p 0.69 1.55E-03 0.75 6.33E-03 1.23E-04 2.18E-02 
miR-654-5p 2.41 1.72E-04 1.37 6.35E-02 1.35E-04 2.18E-02 
miR-195-5p 0.46 8.74E-04 0.62 1.33E-02 1.44E-04 2.18E-02 
miR-744 1.48 2.10E-03 1.36 1.00E-02 2.48E-04 3.29E-02 
mir-1293 2.05 8.56E-03 2.31 2.80E-03 2.78E-04 3.29E-02 
miR-410-3p 1.69 1.30E-03 1.41 1.92E-02 2.90E-04 3.29E-02 
miR-4524a-
5p 0.31 9.42E-04 0.50 2.67E-02 2.91E-04 3.29E-02 
hsa-miR-
502-3p 1.77 1.52E-02 2.22 1.75E-03 3.07E-04 3.29E-02 
hsa-miR-
494-3p 2.53 5.50E-03 2.60 5.95E-03 3.71E-04 3.76E-02 
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Table 3.2. MiRNAs targeting GWAS genes. MiRNA target identification (IPA) filter 
identified 6 of the differentially expressed miRNAs with predicted interactions with 12 of 
the 22 GWAS genes previously identified (listed in Table 1).  
ID Targeted Gene Source IPA Confidence 
hsa-miR-125a-3p DENND1A TargetScan Human High (predicted) 
hsa-miR-1271-5p TOX3 TargetScan Human High (predicted) 
hsa-miR-1271-5p ERBB4 TargetScan Human High (predicted) 
hsa-miR-130b-3p DENND1A TargetScan Human High (predicted) 
hsa-miR-130b-3p ZNF217 TargetScan Human High (predicted) 
hsa-miR-130b-3p RAB5B TargetScan Human High (predicted) 
hsa-miR-130b-3p ERBB4 TargetScan Human High (predicted) 
hsa-miR-130b-3p ERBB3 TargetScan Human High (predicted) 
hsa-miR-130b-3p KCNA4 TargetScan Human High (predicted) 
hsa-miR-195-5p INSR TargetScan Human High (predicted) 
hsa-miR-195-5p YAP1 TargetScan Human High (predicted) 
hsa-miR-195-5p HMGA2 TargetScan Human High (predicted) 
hsa-miR-195-5p RAD50 TargetScan Human High (predicted) 
hsa-miR-410-3p HMGA2 TargetScan Human High (predicted) 
hsa-miR-654-5p GATA4 TargetScan Human High (predicted) 
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3.3.3. A common network of differentially expressed miRNAs and PCOS 
candidate genes may be at work in the PCOS theca: Target prediction revealed that 
~33 % (6/18) of the miRNAs that are differentially expressed between unaffected control 
and PCOS theca cells are predicted to target 55% (12/22) of the GWAS candidate 
genes including DENND1A, which has been previously shown to have a functional role 
in PCOS theca cell steroidogenesis. This led us to hypothesize that like DENND1A, 
other PCOS GWAS candidates may also have significant functional and biological 
relevance to the disorder, possibly in a common network. To test this in silico, IPA core 
pathway analysis was performed on all of the 22 GWAS genes identified thus far to 
examine pathways, networks, diseases and bio-functions that are “over-represented” in 
the GWAS candidates. Several PCOS relevant features were identified in the canonical 
pathways, diseases and biofunctions, physiological system development and functions 
that were over-represented in the GWAS genes dataset and are listed in Table 3.3. 
These results suggested that at least some of the 22 GWAS candidate genes and the 
differentially expressed miRNAs might be involved in a common pathway/ network with 
functional relevance to PCOS pathophysiology central to the theca cells. To investigate 
this, we utilized the “Build Network” application available in IPA and created a network 
with the 22 GWAS genes and overlayed the 18 differentially expressed miRNAs and 
using the “grow” option added any known or predicted connections present in the 
Ingenuity Knowledge Base. The resulting network is represented in Figure 3.1. As 
shown, ~73% (16/22) of PCOS GWAS candidate genes and ~44% (8/18) of 
differentially expressed miRNAs in PCOS theca are a part of a common network.   
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Table 3.3. Ingenuity Pathway Analysis of the PCOS risk loci reported to date.  Key 
findings from the pathway analysis (performed in IPA) of the 22 loci (Table 1.1) 
associated with PCOS risk are described. The Top Canonical Pathways (3.3.A), Top 
Diseases and Bio-functions (3.3.B) and Physiological System Development and 
Functions (3.3.C) over-represented in the PCOS risk loci are shown.  
3.3.A. Top Canonical Pathways  
Name P value Overlap 
Agrin interactions at Neuromuscular Junction 3.80E-05 4.30% 
ErbB Signaling 7.35E-05 3.50% 
Neuregulin Signaling 7.87E-05 3.40% 
Ovarian Cancer Signaling 2.56E-04 2.30% 
ErbB2-ErbB3 Signaling 1.35E-03 3.50% 
 
3.3.B. Top Diseases and Bio-functions 
Name P value # Molecules 
Cancer 9.61E-04 - 4.31E-11 20 
Organismal Injury and Abnormalities 9.61E-04 -4.31E-11 20 
Respiratory Disease 4.34E-04 - 4.38E-10 6 
Endocrine System Disorders 9.60E-04 - 6.83E-09 12 
Reproductive System Disease 9.60E-04 - 6.83E-09 17 
 
3.3.C. Physiological System Development and Function 
Name p-value # Molecules 
Organ Development 9.60E-04 - 4.46E-09 9 
Reproductive System Development and Function 9.60E-04 - 4.46E-09 10 
Organ Morphology 9.6E-04 - 2.81E-08 10 
Renal and Urological System Development and 
Function 8.80E-04 - 2.81E-08 7 
Organismal Development 9.60E-04 - 1.44E-07 10 
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Figure 3.1. IPA network of miRNAs and PCOS candidate genes. Common network 
of the 16/22 PCOS candidate genes and 8/18 of the differentially expressed miRNAs is 
shown. IPA pathway figure legend is described as well. 
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3.3.4. qRT-PCR validation of miRNA expression: Next, we determined the 
expression patterns of all the 8 miRNAs in Figure 3.1. in vitro in 5 unaffected control and 
4 PCOS theca cell cultures treated with and without 20 mM forskolin by TaqMan-based 
miRNA qPCR assays (Life Technologies). Of the 8 miRNAs, statistically significant 
expression differences (P < 0.05) between unaffected control and PCOS theca cells 
were only observed for hsa-miR-125a-3p (Figure 3.2.A) and hsa-miR-130b-3p (Figure 
3.2.B). miR-125a-3p expression was significantly downregulated in PCOS theca cells 
under both basal and forskolin stimulated conditions. MiR-130b-3p expression was 
reduced in PCOS theca cells only under basal conditions. There were no significant 
changes in miR125a-3p and miR-130b-3p expression in response to forskolin treatment 
in unaffected control and PCOS theca cells. 
3.3.5. Decreased miR-125a-3p expression is correlated to increased DENND1A.V2 
expression in PCOS theca cells. Since both miR-125a-3p and miR-130b-3p are 
predicted to target DENND1A, we sought to determine the relation between their 
expression patterns in theca cells. As shown in Figure 3.3, expression of both miRNAs 
was compared against expression of both isoforms of DENND1A, DENND1A.V1 and 
DENND1A.V2, in the same unaffected control (n = 5) and PCOS (n = 4) samples 
treated with and without forskolin. A significant negative correlation was observed 
between expression of miR-125a-3p and DENND1A.V2 (Figure 3.3.A) but no significant 
relation with DENND1A.V1 expression was observed (Figure 3.3.B). No significant 
correlations (P > 0.05) were observed between miR-130b-3p and DENND1A.V2 or 
DENND1A.V1  
In silico miRNA-mRNA target prediction strength was assessed for miR-125a-3p and 
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both isoforms of DENND1A in microRNA.org, which utilizes predicted miR-target 
interactions from miRanda and predicts the probability of miRNA downregulating gene 
expression by calculating mirSVR scores. Positive or miRSVR scores = 0 indicate a null 
probablility of interaction and higher negative scores indicate increasing probability of 
interaction. miR-125a-3p alignment with 3’UTR of DENND1A.V1 gave a mirSVR score = 
-0.0004, whereas miR-125a-3p alignment with 3’UTR of DENND1A.V2 (not present in 
V1) gave a mirSVR score = -1.0634. This preliminary in silico analysis supported our 
observed expression correlation results described above suggesting that the predicted 
interaction of miR-125a-3p with DENND1A is likely more specific for DENND1A.V2 than 
for DENND1A.V1 in theca cells. 
3.3.6. Decreased miR-125a-3p expression in PCOS theca cells is correlated with 
increased DHEA production. Because a relationship between reduced miR-125a-3p 
expression and increased DENND1A.V2 expression was established and as increased 
DENND1A.V2 expression in PCOS is known to be associated with increased androgen 
production (70), we sought to determine whether miR125a-3p expression was 
associated with increased androgen biosynthesis. We examined DHEA accumulation in 
the matched 5 unaffected control and 4 PCOS theca cell preparations under the same 
conditions. As shown in Figure 3.4.A, miR-125a-3p expression has a significant 
negative correlation with DHEA accumulation in theca cells. Interestingly, miR-130b-3p 
(Figure 3.4.B) expression also showed a negative correlation with DHEA accumulation 
but not as significant as with miR-125a-3p and DHEA. 
3.3.7. MiR-125a-3p overexpression in H295R cells downregulates V2 and CYP17 
mRNA expression, but has no effect on V1 expression.  
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In order to confirm specific interaction of miR-125a-3p with V2 and its impact on 
androgen production (as shown by DHEA accumulation), we overexpressed miR-125a-
3p mimic in H295R cells (adrenal corticocarcinoma cell line) and analyzed V1, V2 and 
CYP17 mRNA expression by qRT-PCR in negative-control and mimic treated cells. As 
shown in Figure 3.5.A, mimic treated H295R cells showed a significant decrease in V2 
expression (P = 0.042) when compared to control treated cells. No change in V1 
expression was observed (Figure 3.5.B). In addition, CYP17 expression was also 
significantly downregulated upon mimic overexpression as compared to control, which 
was in agreement to the miRNA-DHEA correlation data shown in Figure 3.4.  
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Figure. 3.2. Decreased miR-125a-3p and miR-130b-3p expression in PCOS theca 
cells. miR-125a-3p and miR-130b-3p expression was compared, by qRT-PCR, in theca 
cells propagated from 5 individual unaffected control and 4 individual PCOS women that 
were treated in the absence (C) and presence of 20 mM forskolin (F) for 16 h.  As 
shown, both, miR-125a-3p (A) and miR-130b-3p (B) expression was decreased in 
PCOS theca cells under basal conditions as compared to unaffected control cells. 
However, only miR-125a expression was significantly reduced under forskolin 
stimulated conditions (*P<0.05) 
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Figure. 3.3. Decreased miR-125a-3p expression is correlated with increased 
DENND1A.V2 expression. qRT-PCR miRNA expression of miR-125a-3p and miR-
130b-3p was compared with qRT-PCR mRNA expression of DENND1A.V1 and 
DENND1A.V2 in same normal (n = 5) and PCOS (n = 4) theca cells. MiR-125a-3p 
expression showed significant negative correlation (Spearman’s ρ = -0.52, P = 0.0279) 
with DENND1A.V2 expression (3.3.A) but showed no significant relation with expression 
of DENND1A.V1 (3.3.B) (Spearman’s ρ = 0.41, P = 0.0874). MiR-130b-3p expression 
showed no significant relationships (P > 0.05) with both DENND1A.V2 (3.3.C) as well as 
DENND1A.V1 (3.3.D), but showed a trend of negative correlation with DENND1A.V2 
(3.3.C, Spearman’s ρ = -0.36) but not with DENND1A.V1 (3.3.D, Spearman’s ρ = 0.39). 
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Figure. 3.4. Decreased miRNA expression is correlated with increased DHEA 
accumulation. qRT-PCR miRNA expression of miR-125a-3p and miR-130b-3p was 
compared with DHEA accumulation (estimated by ELISA) from same unaffected control 
(n = 5) and PCOS (n = 4) theca cell cultures. Significant negative correlation with DHEA 
accumulation was observed with miRNA expression of both miR-125a-3p (3.4.A, 
Spearman’s ρ = -0.56, P = 0.0156) and miR-130b-3p (3.4.B, Spearman’s ρ = -0.48, P = 
0.0408) 
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Figure. 3.5. MiR-125a-3p overexpression in H295R cells downregulates V2 and 
CYP17 mRNA expression, but has no effect on V1 expression. qRT-PCR mRNA 
expression for V1, V2 and CYP17 genes was analyzed in H295R cells treated with miR-
125a-3p mimic (75nM) and negative control mimic (75nM) for 48 hours. MiR-125a-3p 
overexpression causes a down-regulation of V2 (P = 0.042) and CYP17 (P = 0.0237) 
mRNA expression when compared to control. No significant differences in V1 
expression were observed (P > 0.05). 
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3.4. Discussion    
PCOS is a complex disorder.  Recent GWAS have identified candidate loci, some of 
which have been replicated by multiple laboratories, providing a basis for the molecular 
dissection of the pathophysiology of PCOS (34–37). Theca cells, the androgen 
producing cells of the ovary and central to PCOS pathophysiology, also have evidence 
of an altered transcriptome profile in PCOS, which could be contributed by, at least in 
part, by miRNA regulation. (77,78). However, a detailed study of miRNA expression and 
target gene analysis has not been performed in theca cells. Altered miRNA levels have 
been associated with several phenotypes in the PCOS spectrum including diabetes, 
insulin resistance and inflammation. An increasing number of studies are showing 
differential miRNA expression in the ovarian stroma, follicular fluid, cumulus cells and 
granulosa cells of women with PCOS (63,64,79–81,86,87). Our study is the first to 
identify differential miRNA expression in theca cell cultures from PCOS women as 
compared to normal cycling women.  
The first GWAS conducted on Han Chinese populations identified 11 loci with significant 
associations with PCOS (34,35). The association of some of the loci identified in these 
studies including DENND1A, RAB5B and THADA to PCOS has also been replicated in 
European populations (38–40). Subsequent GWAS conducted on women of European 
descent identified other loci including ERBB2, ERBB3, ERBB4, RAD50, KRR1, FSHB, 
GATA4, NEIL2 and KCNA4 and also replicated association of some of the Han Chinese 
GWAS including YAP1, THADA, DENND1A and C9orf3 (36,37). Of the total 22 loci 
identified in the 4 GWAS, association with some candidate genes including INSR, 
FSHR, LHCGR and GATA4 is plausible because of their known roles in reproductive 
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biology /ovarian function and their involvement in PCOS candidate gene studies. For 
e.g. FSHR and LHCGR are gonadotropins involved in regulation of folliculogenesis and 
ovulation. The INSR gene is involved in insulin metabolism and can play a crucial role in 
PCOS pathophysiology via insulin resistance. GATA4 is a transcription factor known to 
be differentially expressed in PCOS granulosa and theca cells and is speculated to be 
involved in transcriptional activation of PCOS relevant genes including CYP17, which is 
responsible for androgen production. (8,24). However, the functional relevance of the 
remaining loci with PCOS is not clear and the exact molecular mechanism by which any 
of these candidate genes may contribute to the disorder is not known. Genotype-
phenotype correlation studies of the susceptibility SNPs identified by GWAS have 
yielded low to modest relative risk ratios (41,88). This is not unexpected for a complex 
disorder like PCOS and establishing a causal relationship between the genetic variants 
identified in GWAS and pathophysiological phenotype is challenging. In a previous 
study, we demonstrated that a splice variant (DENND1A.V2) of DENND1A, one of the 
candidate genes identified in the Han Chinese GWAS and replicated in studies of 
women of European ancestry is involved in PCOS theca cell steroidogenesis (69,70). In 
the present study, we show that 6 of the 18 differentially expressed miRNAs in PCOS 
theca cells are predicted to target 12 of the 22 PCOS candidate genes identified in 
GWAS including DENND1A.  
IPA pathway analysis of the 22 GWAS genes revealed an over-representation of 
several PCOS relevant features. Three of the top 5 canonical pathways are central to 
ovarian function and PCOS pathophysiology including ovarian cancer signaling, ErbB 
signaling and ErbB2-ErbB3 signaling. Although there is no firm evidence for 
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associations between PCOS and ovarian cancers because of limited sample sizes and 
confounding risk factors, perturbation of pathways in ovarian cancer are important for 
normal ovarian function (89). Ovarian morphology is altered in PCOS, which can be 
explained by changes in cellular growth and proliferation pathways, which overlap with 
ovarian cancer signaling. ErbB2, ErbB3 and ErbB4 are epidermal growth factors 
receptors, and EGFR signaling plays a crucial role in ovarian steroidogenesis and 
oocyte maturation (90,91). GWAS genes also show an over-representation of diseases 
and disorders that are highly concordant with PCOS including organismal injury and 
abnormalities, endocrine system disorders and reproductive system disorders, with 20, 
12 and 17 molecules respectively, from the GWAS genes dataset being significantly 
overrepresented in these diseases/ disorders. The physiological system development 
and functions also had similar trends with organ development, reproductive system 
development and function as well as organ morphology with 9, 10 and 10 molecules 
respectively. The top IPA network which had ~45% (10/22) of the GWAS genes had a 
network score of 24 and associated network functions including cancer, organismal 
injury and abnormalities and respiratory disease. These results suggested that more 
than one PCOS candidate gene are involved in PCOS pathophysiology, which warrants 
detailed study of other GWAS candidate genes in a PCOS context for e.g. compare 
gene expression patterns of the GWAS candidate genes in control unaffected and 
PCOS theca cell cultures.  
Overlaying the GWAS genes network with the 18 differentially expressed miRNAs 
identified in this study revealed ~73% (16/22) PCOS GWAS candidate genes and ~44% 
(8/18) differentially expressed miRNAs in PCOS theca to be a part of a common 
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network. Our qPCR assays validated the expression patterns of some of these miRNA-
target gene pairs in vitro in theca cells, including hsa-miR-125a-3p and hsa-miR-130b-
3p down-regulation and increased expression of DENND1A isoform DENND1A.V2 in 
PCOS theca cells.  
There are studies demonstrating that hsa-miR-93 is differentially expressed in PCOS, 
with evidence for decreased expression in human PCOS blastocysts (92) and increased 
expression in human PCOS adipocytes (93), granulosa cells (94) as well as in 
circulation (95). Target identification in IPA revealed that miR-93 is predicted to target 
(“High” confidence level) 3 of the 11 GWAS genes: RAB5B, ZNF217 and THADA. 
However, we did not find any differences in miR-93 expression levels in PCOS theca 
cells in our sequencing as well as TaqMan based qPCR assays 
It is important to note that this study provides further evidence for the functional role 
played by DENND1A in PCOS as both the miRNAs, hsa-miR-125a-3p and hsa-miR-
130b-3p, whose differential expression in PCOS theca has been validated in vitro, are 
predicted to target the DENND1A. The gene is also a part of the common network 
shown in Figure 3.1. In addition, decreased miR-125a-3p expression is correlated with 
increased DENND1A.V2 expression and increased DHEA accumulation, which is 
characteristic of PCOS cells. The miR-125a-3p mimic studies in addition confirmed that 
the predicted interaction of miR-125a-3p & DENND1A is specific for V2 and not V1. 
Decreased miR-125a-3p expression can possibly explain, at least in part, the V2 
overexpression in PCOS theca cells as documented previously, which was not 
explained by any of the other genetic mechanisms investigated by Tee et al and 
described in Chapter 2 in this thesis. (42,69). MiRNAs are usually involved in complex 
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regulatory networks and their expression patterns are themselves regulated by several 
factors. Even though a significant association between miR-130b-3p and DENND1A.V2 
was not observed, a trend for inverse correlation with DENND1A.V2 but not V1 was 
found and miR130-3p was inversely correlated with DHEA production. Thus, further 
investigation of miR130-3p with respect to PCOS pathophysiology is warranted. 
In addition to DENND1A and miR-125a-3p and miR-130b-3p, there are other genes in 
the network that deserve further discussion including YAP1 and ZNF217. Though not a 
lot is not known about these genes in the context of reproduction, we have evidence 
showing that an isoform of YAP1 – YAP1.V2 and ZNF217 are significantly 
downregulated in PCOS theca cells as compared to unaffected control theca cells and 
reduced expression is correlated with increased DHEA accumulation. (Data not shown) 
MiRNA - target gene interactions are complex and as mentioned above, correlated 
inverse expression patterns are not always possible to observe as each gene can be 
regulated by multiple miRNAs. Performing luciferase-reporter assays is crucial to 
confirm the miRNA-target gene interaction in vitro. Even though, expression patterns 
are not directionally correlated with the expression patterns of the miRNAs predicted to 
target these genes, it is important to note that two other PCOS GWAS candidate genes 
from the same network show evidence for differential expression associated with 
functional relevance of increased androgen production that is central to PCOS.   
These results suggest a potential epigenetic mechanism (in lieu of miRNA regulation) of 
V2 overexpression in PCOS theca cells via miR-125a-3p regulation. These results also 
support our hypothesis that miRNAs and DENND1A are involved in a complex network, 
perhaps in combination with other GWAS genes and can explain the ovarian 
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hyperandrogenemia associated with and central to PCOS.  
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Chapter 4: Rare Mutations and Potentially Damaging Missense Variants in Genes 
Encoding Fibrillar Collagens and Proteins Involved in Their Production Are 
Candidates for Risk for Preterm Premature Rupture of Membranes 
 
Please note: This chapter is under review at PLoS One as 
Bhavi Modi, Maria Teves, Laurel Pearson, Hardik Parikh, Piya Chaemsaithong, Nihar 
Sheth, Tim York, Roberto Romero, Jerome Strauss. Rare Mutations and Potentially 
Damaging Missense Variants in Genes Encoding Fibrillar Collagens and Proteins 
Involved in their Production are Candidates for Risk for PPROM.   
 
 
 
Abstract 
Preterm premature rupture of membranes (PPROM) is the leading identifiable cause of 
preterm birth with ~ 40% of preterm births being associated with PPROM and occurs in 
1% - 2% of all pregnancies. We hypothesized that multiple rare variants in fetal genes 
involved in extracellular matrix synthesis would associate with PPROM, based on the 
assumption that impaired elaboration of matrix proteins would reduce fetal membrane 
tensile strength, predisposing to unscheduled rupture. We performed whole exome 
sequencing (WES) on neonatal DNA derived from pregnancies complicated by PPROM 
(49 cases) and healthy term deliveries (20 controls) to identify candidate 
mutations/variants. Genotyping for selected variants from the WES study was carried
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out on an additional 188 PPROM cases and 175 controls. All mothers were self-
reported African Americans, and a panel of ancestry informative markers was used to 
control for genetic ancestry in all genetic association tests. In support of the primary 
hypothesis, a statistically significant genetic burden (all samples combined, SKAT-O p-
value = 0.0225) of damaging/potentially damaging rare variants was identified in the 
genes of interest - fibrillar collagen genes, which contribute to fetal membrane strength 
and integrity. These findings suggest that the fetal contribution to PPROM is polygenic, 
and driven by an increased burden of rare variants that may also contribute to the 
disparities in rates of preterm birth among African Americans. 
 
4.1. Introduction 
Although there is strong evidence from twin-based studies that both maternal and fetal 
genetic factors contribute to preterm birth, attempts to identify specific loci contributing 
to prematurity in genome-wide association studies (GWAS) have largely failed to yield 
robust and reproducible findings (54,59,96–98). A number of candidate gene 
association studies have found significant relationships, but meta-analyses indicate that 
these associations are at best weak or population-specific (50,99,100). The 
disappointing output from genetic studies may relate to the subject inclusion and 
exclusion criteria, including the proximate cause of preterm birth - spontaneous preterm 
birth (sPTB) or preterm premature rupture of membranes (PPROM), population 
heterogeneity (partially attributable to genetic admixture), and environmental exposures, 
including viral and bacterial infections. Further, identification of genetic variants 
contributing to preterm birth risk is mostly based on the “common disease-common 
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variant” hypothesis, which assumes that a large number of common allelic variants can 
explain the genetic variance in complex diseases. This approach has been employed 
for several complex traits such as human height and schizophrenia and despite having 
large sample sizes required for success, there still exists an issue of “missing 
heritability” with identified variants being able to explain only a small fraction of the 
genetic variance observed (101). Considering the complex genetic nature of preterm 
birth, a systematic identification of even a small number of rare variants with moderate-
large effect sizes in genes of known/putative biological significance can be helpful 
(54,102).  None of the genetic studies on preterm birth so far have taken this approach.  
PPROM is the leading identifiable cause of preterm birth, with ~40% of preterm 
deliveries being associated with PPROM (48). Previous studies have focused on 
selected candidate genes involved in infection/ inflammation pathways, with the majority 
of these studies investigating only maternal genomes (47,50,60,103,104) despite 
evidence of a fetal contribution established by twin studies (59,97). 
Human fetal membranes consist of an inner layer, the amnion, and an adherent outer 
layer, the chorion. The amnion is the load-bearing component of the fetal membranes 
and major contributor to their structural integrity. The strength of the fetal membranes is 
influenced by both synthesis and degradation of the extracellular matrix (ECM) 
components. Fibrillar collagens and associated proteins are major components of the 
fetal membranes contributing to their tensile strength (105,106). Thus, defects in the 
fibrillar collagen synthesis and/or altered ECM metabolism can adversely affect fetal 
membrane integrity, and may result in preterm birth as a result of preterm rupture. 
Epidemiological studies show that fetuses/neonates with Ehlers-Danlos syndrome, 
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osteogenesis imperfecta, and restrictive dermopathy, disorders of ECM synthesis, are 
at increased risk of adverse pregnancy outcomes including PPROM (106–109).  In 
addition, a functional promoter SNP in the SERPINH1 gene, which encodes a 
chaperone protein (HSP47) necessary for fibrillar collagen synthesis, was previously 
shown to be associated with PPROM (110). 
The primary hypothesis explored in this study is that PPROM is the result of rare 
mutations or variants in the fetal genes involved in the elaboration of the amnion ECM. 
An initial Whole Exome Sequencing (WES) was performed followed up by genotyping of 
select variants in additional samples of neonatal DNA from normal term pregnancies 
(controls) and pregnancies complicated by PPROM (cases). All of the neonates were 
delivered from mothers of self-reported African-American ancestry.  In an effort to 
identify functional variants with large effect, the analysis was selectively focused on 
damaging mutations: either nonsense mutations or frameshift mutations that precluded 
production of a functional protein, and missense mutations, which were predicted to be 
damaging or potentially damaging. Furthermore, the investigation was restricted to 
genes whose disruption could theoretically promote PPROM by weakening the fetal 
membranes by disruption of the ECM fibrillar collagens and genes encoding proteins 
involved in their production.  
We discovered that rare heterozygous, nonsense, frameshift and damaging missense 
mutations were more prevalent in the genomes of neonates born of pregnancies 
complicated by PPROM as compared to normal term controls. The combined burden of 
the rare damaging variants identified in the fetal genome yielded a statistically 
significant genetic association with PPROM.  These results suggest that PPROM may 
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be caused by infrequent genetic variants that modulate fetal membrane strength leading 
to weakening of the membranes and ultimately ending in premature rupture.  
 
4.2. Materials and Methods 
4.2.1. Study Population: The initial WES was performed on 49 case and 20 healthy 
term control neonatal DNA samples. Additional genotyping of select variants was 
performed on an independent cohort of 188 case and 175 control neonatal DNA 
samples. Subjects were self-reported African-American women and their neonates 
receiving obstetrical care at MCV Hospitals, Richmond, VA (all samples in the initial 
WES) and Hutzel Hospital in Detroit, MI. The study was approved by the respective 
Institutional Review Boards and written informed consent was obtained from mothers 
before sample collection. Demographic and clinical data were obtained from surveys 
and medical records. Control DNA samples (n = 20 + 175) were obtained from neonates 
of singleton pregnancies delivered at term (> 37 weeks of gestation) of mothers with no 
prior history of PPROM or preterm labor. Cases of PPROM (n = 49 + 188) were defined 
as neonates from pregnancies complicated by spontaneous rupture of membranes prior 
to 37 weeks of gestation. The diagnosis of membrane rupture was based on pooling of 
amniotic fluid in the vagina, amniotic fluid ferning patterns and a positive nitrazine test. 
Women with multiple gestations, fetal anomalies, trauma, connective tissue diseases 
and medical complications of pregnancy requiring induction of labor were excluded.  
4.2.2. Ancestry Estimates: Genetic ancestry was estimated to control for the presence 
of population structure in all genetic association tests. Genetic ancestry estimates were 
generated in a two-way model of admixture, European and West African, for the 
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neonates of each self-reported African-American study subject using 102 ancestry 
informative markers (AIMs), single nucleotide polymorphisms with large allele frequency 
differences between ancestral populations (Appendix, Table A.4.1). Prior allele 
frequencies derived from the HapMap West Africans (YRI, Yoruba in Ibadan, Nigeria) 
and Europeans (CEU, CEPH Utah residents with ancestry from northern and western 
Europe) were used to estimate individual genetic ancestry estimates following a 
maximum likelihood approach with mean allele frequency difference between ancestral 
populations (δ = 0.733) (111–113).  
4.2.3. Whole Exome Sequencing: Whole Exome Capture and Sequencing was 
performed on the initial set of samples at BGI (BGI, Cambridge, MA) using the 
SureSelect Target Enrichment System Capture Process and high-throughput 
sequencing on an Illumina HiSeq2000 platform. Raw image files are processed by 
Illumina base calling Software 1.7 for base calling with default parameters and the 
sequences of each individual are generated as 90bp paired-end reads. The raw 
sequence data generated from the Illumina pipeline were used for bioinformatic 
analysis. 
4.2.4. Read Mapping and pre-processing: Raw sequence data for each individual 
were mapped to the human reference genome (build hg19) using the BWA-MEM 
algorithm of Burrows-Wheeler Aligner (v 0.7.12) (114). This was followed by a series of 
pre-processing steps – marking duplicates, realignment around indels and base quality 
recalibration. PCR duplicates were marked within the aligned reads using Picard tools. 
(http://picard.sourceforge.net) Next, mapping artifacts around indels were cleaned up 
using the RealignerTargetCreator, the IndelRealigner and the LeftAlignIndels walkers of 
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the Genome Analysis ToolKit (GATK) (115,116). Inaccurate / biased base quality scores 
were recalibrated using the BaseRecalibrator, the AnalyzeCovariates and the 
PrintReads walkers of GATK, which use machine learning to model these errors 
empirically and adjust the quality scores accordingly. Alignment statistics for each 
sample were calculated on the “clean” sample BAM files. 
4.2.5. Variant Discovery and Quality Filtering: The pre-processing steps were 
followed by variant calling using the HaplotypeCaller walker of GATK on each sample 
BAM file. Variant sites are identified by taking into account the haplotype likelihood 
predicted by building Dr. Brujin-like graphs in regions where the data displays variation 
relative to the hg19 reference genome. This step is also guided using the dbSNP, and 
Mills and 1000G gold standard SNP and indel databases. The output is a set of 
unfiltered/raw SNP and indel calls in the Genomic Variant Call Format (gVCF) file. 
Sample-specific gVCFs were merged into a single VCF file and a cohort-wide joint 
genotyping was performed using the CombineGVCFs walker of GATK. Finally, Variant 
Quality Score Recalibration (VQSR) was performed to assign the statistical probability 
to each variant call and produce a call-set distilled to a desired level of truth sensitivity. 
The raw SNP call-set was filtered using the GATK VariantFilter module, with variants 
required to pass the following criteria – “QUAL >= 30” AND “DP >= 25”. The raw indel 
call-set was filtered with variants required to pass the following criteria – “QD > 2.0” 
AND “FS < 200.0” AND “InbreedingCoeff > -0.8” AND “ReadPosRankSum > -20.0". 
4.2.6. Annotation and Filtering for Genes and Variants of Interest: SnpEff was used 
for annotating the functional effects of high-quality SNPs and INDELs on genes, 
transcripts and protein sequences including: a) their genomic location (i.e., intron, 5’ or 
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3’ untranslated region, upstream/downstream of a transcript, or intergenic region); b) 
their consequence on protein sequence (i.e., stop-gained, missense, frameshift); c) 
known variants from dbSNP (117), ClinVar  (118), and the 1000 Genomes Project 
(119). 
A total of sixteen candidate genes were selected for investigation of rare variants based 
on their involvement in the extra-cellular matrix (ECM) composition and synthesis and 
previously linked to connective tissue disorders such as classical types of Ehlers-Danlos 
syndrome (types I and II) as well as Ehler’s-Danlos Syndrome types VIIA and VIIB, 
osteogenesis imperfecta type II and restrictive dermopathy (106). These genes encode 
for major ECM components including fibrillar collagens (COL1A1, COL1A2, COL2A1, 
COL3A1, COL5A1, COL5A2) and associated proteins (CRTAP, ELN) as well as 
enzymes involved in collagen processing and ECM production (ADAMTS2, BMP1, 
LEPRE1, LOX, LOXL1, SERPINH1, ZMPSTE24, FKBP10). Further analyses were 
focused on variants affecting only coding regions of the selected genes to best identify 
functional variation and this included nonsense, frameshift, splice site and damaging 
missense variants. Damaging missense variants were selected on the basis of most 
deleterious predictions in both Polyphen2 (HumDiv - probably damaging) as well as 
SIFT (damaging) platforms. When multiple isoforms were identified, only variants with 
the most deleterious damaging predictions for all isoforms were included.  
4.2.7. Custom Genotyping: The variants identified and selected for further analysis 
from Whole Exome Sequencing (Table 4.2) were validated and additional samples (an 
independent cohort of additional 188 cases and 175 controls) were genotyped for the 
selected variants. Genotyping was performed on the Agena (previously Sequenom) 
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MassArray iPLEX platform following manufacturer’s instructions (120) at the University 
of Minnesota Genomics Center. 
4.2.8. Testing for Genetic Association: The combined set of variants identified in the 
initial WES and by additional genotyping were tested for genetic association using the 
combined Optimized Sequence Kernel Association Test (SKAT-O) software package in 
R version 3.2.3 (121–123) with default parameters adjusting for small sample size and 
ancestry estimates as covariates. A burden test was selected because the variants 
under study were rare (variant frequency in sample set < the calculated fixed frequency 
threshold T = 0.034), in the coding region and known/ expected to alter amino acid 
sequence and thus assumed to contribute to risk with same direction if effect (124). 
4.2.9. Statistical Analysis: Mean levels of demographic variables were tested using a 
2-tailed Student’s t-test. Count data (for gravidity and parity) was square-root 
transformed before performing tests. P-values < 0.05 were considered statistically 
significant. 
 
4.3. Results 
4.3.1. Study Population: The characteristics of the subjects used in the study are 
presented in Tables 4.1.A and 4.1.B. There were no significant differences in maternal 
age, gravidity and parity between the cases and controls.  As expected, the pregnancies 
complicated by PPROM had a significantly shorter gestational age at delivery than the 
term pregnancy control group (p < 0.001) and the PPROM neonatal birth weights were 
also significantly lower (p < 0.001) for both sample sets. Individual neonatal genetic 
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ancestry estimates were calculated and used to compare the ancestry proportions 
between cases and controls and no differences were found. (Appendix, Table A.4.1) 
4.3.2. Variant Discovery: The analysis of WES was focused on damaging mutations 
(non-sense and frameshift mutations) and predicted damaging missense variants as 
identified by SIFT and Polyphen2 in the preselected genes of interest in neonatal DNA 
derived from of 49 pregnancies complicated by PPROM and 20 normal term 
pregnancies. 
4.3.3. Variants Identified in Genes involved in ECM Components and ECM 
Synthesis: The variants identified in the selected genes of interest in the initial WES 
are described in Table 4.2. The position-specific annotation of the variant in the protein 
(“within feature” column) describes the molecular processing outcome of that particular 
region in the final protein product. An additional 188 cases and 175 controls were 
genotyped for these variants.  
In the discovery WES, all variants identified were unique to cases. A heterozygous 
nonsense mutation in BMP1 (rs116360985), an enzyme involved in procollagen 
processing, was discovered in 1 PPROM case. This mutation truncates the protein at 
amino acid residue 721 in a protein that has an isoform of 730 amino acids, so the 
functional significance is not clear. A frameshift mutation (rs137853883) in the FKBP10 
gene, which encodes for a chaperone protein involved in ECM metabolism, was 
identified in 1 case. Heterozygous predicted damaging (Polyphen2 and SIFT) missense 
variants were found in COL1A2; rs139528613 in 3 cases and rs145693444 in 2 PPROM 
cases. Predicted damaging heterozygous missense variants were found in COL5A1 
(rs2229817, rs116003670 and rs61739195) in 3 different PPROM cases.  Although 
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rs61739195 and rs2229817 are predicted to be damaging by both Polyphen 2 and 
SIFT, these variants are listed to be benign in ClinVar.  All other mutations and 
missense variants are listed as having unknown clinical significance.  
Interestingly, two missense variants, rs201234519 and rs78690642, both predicted to 
be damaging by Polyphen2 and SIFT were identified in COL2A1, which encodes a 
fibrillar collagen found in cartilage and tendons, and not previously thought to be 
expressed in amnion. Rs78690642 was present in 5 cases and rs201234519 was 
present in one different case with none of the controls having either of the two variants. 
We performed an RT-PCR on RNA extracted from fetal membranes from normal term 
pregnancies (n = 6) using COL2A1 specific primers, and obtained a robust amplicon 
that was sequence-verified to be COL2A1 mRNA (Appendix, Figure A.4.1).  Thus, it is 
possible that COL2A1 mRNA, and possibly protein, is expressed in fetal membranes, 
and this has been overlooked in previous studies.   
None of the heterozygous variants in the COL1A2, COL2A1 and COL5A1 genes 
appeared in the same subject. However, one case had a predicted damaging mutation 
in COL1A2 (rs139528613) as well as a nonsense mutation in BMP1 (rs116360985).  
Missense variants that were not predicted to be damaging using our stringent criteria 
were found in the fibrillar collagen genes as well as genes involved in their synthesis 
(Appendix, Table A.4.2).  A number of these variants were novel and only detected in 
cases.  In some instances one of the predictive algorithms suggested that the variant 
was potentially damaging (e.g., rs201944190), but their significance with respect to 
PPROM remains to be evaluated.   
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Observed allele frequencies for both the initial WES as well as the follow up study are 
shown in Table 4.3.  In total, WES identified 7 predicted to be damaging missense 
variants in the candidate genes involved in ECM formation in 14 cases, one frameshift 
variant in FKBP10 and one nonsense mutation in BMP1 in one case each and none in 
the 20 controls. In addition, the follow-up study revealed an increased burden of the 
damaging missense variants in 10 additional cases and 6 controls. The nonsense 
mutation in BMP1 was identified in an additional 4 cases and 5 controls and the 
frameshift variant in FKBP10, was not found in any of the additional samples 
genotyped. Combining the two sample sets revealed an increased frequency of the risk 
allele in cases as compared to controls.  
4.3.4. Genetic Association Analysis: To determine if the rare variants collectively 
contributed to PPROM risk, we performed a genetic burden test using the combined 
initial WES and follow up genotypes including adjustment for West African ancestry. 
The omnibus SKAT-O test yielded a significant association for the rare variants with 
PPROM (p-value = 0.0225). 
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Table 4.1.A. Characteristics of the study population in the initial WES set 
Cases (n = 49) and Controls (n = 20) were compared for key patient characteristics. 
Values represent means with SDs reported in parentheses for each group.  
Characteristic 
Cases 
Mean  (SD) 
Controls 
Mean  (SD) 
p-value 
Maternal Age (years) 27.57 (5.67) 25.8 (4.86) 0.198 
Gestational Age at Delivery (weeks) 29.59 (4.17) 38.55 (1.19) < 0.001 
Neonatal Weight (kgs) 1.47 (0.65) 3.21 (0.53) < 0.001 
Gravidity 1.73 (0.54) 1.78 (0.48) 0.685 
Parity 0.85 (0.72) 1.04 (0.62) 0.280 
 
Table 4.1.B. Characteristics of the study population used for follow-up 
genotyping. 
Cases (n = 188) and Controls (n = 175) were compared for key patient characteristics. 
Values represent means with SDs reported in parentheses for each group.  
CCCharacteristic 
Cases 
Mean (SD) 
Controls 
Mean (SD) 
p-value 
Maternal Age (years) 26.76 (5.91) 26.6 (6.02) 0.798 
Gestational Age at Delivery (weeks) 31.05 (3.63) 39.47 (0.10) < 0.001 
Neonatal Weight (kgs) 1.7 (1.07) 3.35 (0.31) < 0.001 
Gravidity 1.91 (0.59) 1.89 (0.58) 0.09 
Parity 1.06 (0.77) 1.10 (0.69) 0.62 
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Table 4.2. Variants identified in genes involved in ECM composition and 
synthesis The positional and putative functional impact of the variants identified in the 
initial WES (unique to cases in the WES) in the selected genes of interest and selected 
for additional genotyping are shown. (PPD: Propeptide = part of a protein that is cleaved 
during maturation or activation, chain = extent of polypeptide chain in the mature 
protein). 
Gene SNP ID Location 
Allele 
Change 
Type 
AA Position 
(Residue 
Change) 
Within 
Feature 
BMP1 rs116360985 Chr8: 22058684 C > T Nonsense 721 (R > Ter*) Chain 
FKBP10 rs137853883 Chr17:39975558 - > C Frameshift 278 (G > R) Chain 
COL1A2 rs139528613 Chr7: 94028386 G > A Missense 41 (R > H) PPD 
COL1A2 rs145693444 Chr7: 94038721 G > T Missense 294 (V > F) Chain 
COL2A1 rs201234519 Chr12:48391685 G > T Missense 64 (P > H) PPD 
COL2A1 rs78690642 Chr12:48367327 C > T Missense 1374 (G > S) Chain 
COL5A1 rs116003670 Chr9:137582842 G > A Missense 65 (R > Q) Chain 
COL5A1 rs2229817 Chr9:137726950 C > T Missense 1757 (T > M) PPD 
COL5A1 rs61739195 Chr9:137708884 C > T Missense 1379 (P > S) Chain 
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Table 4.3. Allele frequencies of the variants identified  
The table shows the allele frequencies of the putative risk allele (RAF) of variants listed 
in Table 4.2 in the general populations of CEU - Northern Europeans from Utah 
(European-American), AFR –African (combined African populations) and ASW – 
Americans of African ancestry in Southwest USA (admixed African Americans) 
ancestries as reported in the 1000 Genomes Project [50] and their observed risk allele 
frequencies in the initial WES and in the follow up study on an independent sample 
cohort used for custom genotyping, separate and combined. Please note that the AFR 
allele frequencies constitute a super population, which includes the allele frequencies 
from all African populations in the 1000 Genomes Project including the ASW. 
SNP ID 
RAF in 
CEU/AFR/ASW 
(1000 genomes) 
RAF in 
Initial WES 
Case/ Control 
RAF in 
Follow-Up 
Case/ Control 
RAF in 
Combined 
Case/ Control 
rs116360985 0.000/0.005/ 0.000 0.01/ 0 0.011/ 0.014 0.011/ 0.013 
rs137853883 NA 0.01/ 0 0/ 0 0.002 / 0.00 
rs139528613 0.000/0.011/ 0.025 0.031/ 0 0.006/ 0.009 0.011/0.008 
rs145693444 0.000/0.004/ 0.008 0.02/ 0 0/ 0 0.004/ 0 
rs201234519 0.000/0.002/ 0.000 0.01/ 0 0.006/ 0 0.006/ 0 
rs78690642 0.000/0.014/ 0.025 0.05/ 0 0.009/ 0.003 0.018/ 0.003 
rs116003670 0.000/0.007/ 0.000 0.01/ 0 0.006/ 0.006 0.006/ 0.005 
rs2229817 0.000 /0.001/ 0.008 0.01/ 0 0.003/ 0 0.004/ 0 
rs61739195 0.005 /0.000/ 0.000 0.01/ 0 0/ 0 0.002/ 0 
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4.4. Discussion 
The present study using WES to identify mutations and damaging variants in the 
neonatal genome associated with PPROM supported the working hypotheses that rare 
variants could be significant contributors to preterm birth, particularly mutations or 
variants that would alter ECM integrity, resulting in weaker fetal membranes or 
increased susceptibility of ECM proteins to proteolytic enzymes. 
Crosslinked networks of several collagen types constitute the major components of the 
ECM of the fetal membranes. Altered expression patterns or altered metabolism of any 
of the ECM or collagen components could lead to a loss of integrity of the fetal 
membranes (105,106). Some studies have shown that PPROM membranes have an 
altered amnion collagen content as compared to normal term pregnancies (125–127). 
We anticipated identifying variants that would disrupt the ECM, and looked for mutations 
and variants in genes encoding proteins involved in the production of the major ECM 
proteins in fetal membranes, especially variants that would alter the collagen content or 
structure of the amnion. With the exception of BMP1 and FKBP10, we discovered no 
damaging mutations (nonsense, frameshift, splice junctions) in the selected genes of 
interest. BMP1 is a metalloproteinase involved in collagen processing. FKBP10 codes 
for a chaperone protein, FKBP65, which is known to be associated with the extracellular 
matrix protein - tropoelastin. Mutations in FKBP10 have been found in several family 
members with osteogenesis imperfecta and clinical consequences of these mutations, 
one of which is the frameshift mutation identified in our study (rs137853883), included 
loss of FKBP65 protein function leading to delayed type I procollagen secretion and 
improper crosslinking of collagen (128,129).  
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The tensile strength of fetal membranes is determined by the assembly of fibrillar 
collagens (I, III, V) into fibrils. The size of the fibrils is mainly determined by type V 
collagen in association with types I and III collagens and proteoglycans (105,130). Both 
COL5A1 and COL5A2 are involved in the production of type V collagen, which 
participates in early fibril initiation, determination of fibril structure and matrix 
organization (131,132). Type I collagen is involved in fibril formation and consists of two 
alpha-1 chains (COL1A1) and one alpha-2 chain (COL1A2). Mutations in the COL1A1 
and COL1A2 genes are known to cause rare forms of Ehler’s Danlos Syndromes, types 
VIIA and B and osteogenesis imperfecta types I and II (106,133,134). Mutations in 
COL5A1 and COL5A2 genes resulting in haploinsufficiency or structural modifications of 
type V collagen are common causes for classical Ehler’s Danlos Syndrome (types I and 
II) (135). These disorders have been associated with increased risk of PPROM when 
the fetus/neonate is affected (106,107,109). A case-control study with case-parent 
triads and case-mother dyads suggested a significant association of COL5A1 
(combined fetal-maternal association) and COL5A2 (fetal association) with spontaneous 
preterm birth (131). Our study identified several predicted to be damaging missense 
variants in the COL1A2 and COL5A1 genes that were unique to only cases in the initial 
WES. Missense variants were identified in the COL1A1, COL3A1 and COL5A2 genes 
but their predicted impact on protein function was benign.  
Potentially damaging missense variants in the COL2A1 gene were also discovered with 
increased frequency in PPROM cases. COL2A1 codes for cartilage collagen and until 
now there has been no evidence of COL2A1 expression in the amnion making the 
significance of this finding uncertain (136).  However, human amniotic membranes 
	 81	
(HAM) have been used as a source of stem cells for chondrocyte culture, where 
chondrocytes grown on the chorionic side of the HAM express type II Collagen 
(137,138). RT-PCR using mRNA from fetal membranes (amnion) obtained from normal 
term pregnancies and COL2A1 specific primers, revealed detectable COL2A1 mRNA 
expression, raising the possibility of low levels of expression of COL2A1 protein that 
might play a significant role in fetal membrane integrity.  Alternatively, the detected RNA 
could be generated from illegitimate transcription of the COL2A1 gene. The putative 
functional significance of the variants could be due to variants in genes that are in 
linkage disequilibrium with the COL2A1 SNPs or they could have a disrupting impact on 
overlapping coding sequences on the DNA strand opposite the COL2A1 gene. A 
noncoding RNA (LOC105369752) of unknown function does reside there. There was no 
linkage disequilibrium (LD) information available for rs201234519. Rs78690642 is in LD 
with three other SNPs in the COL2A1 gene (rs1455684563, rs76519927 and 
rs2071358).  
It is important to note that there are significant disparities in the prevalence rates of 
PPROM with African-American women experiencing a 2-fold increased risk of PPROM 
as compared to European-American women. This disparity cannot be explained by 
socio-economic factors alone and genetic variation and gene-environment interactions 
are involved (49,50). Most of the rare variants described in this study are more 
prevalent in individuals of West African descent than European descent in the general 
population. Interestingly, this is also true for the SERPINH1 promoter SNP that has 
previously been associated with PPROM (110). Admixed populations such as the 
African Americans have varying proportions of West African and European genetic 
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ancestry contributions across individuals and also differences in groups across different 
regions within the US (139,140). Even though the sample set in our initial WES and the 
independent sample set on which custom genotyping was performed consist of 
individuals from two different regions, Richmond and Detroit respectively, the fact that 
their combined SKAT-O gives a significant association is promising, suggesting a higher 
functional impact of the rare variants identified. Moreover, the fact that the combined 
burden of rare variants, which are of African origin (all except rs61739195), is 
significantly associated with increased PPROM risk suggests that the increased 
prevalence of PPROM in African-American populations is partly attributed to these rare 
population-specific alleles.  
There are potentially other rare variants inactivating transcription factors or disrupting 
transcription factor binding sites that might result in reduced production of fibrillar 
collagens in the amnion.  These were not explored in our study, nor were epigenetic 
factors that could influence collagen gene expression.   These should be explored in 
future research. Conversely, variants that affect expression of matrix degrading 
enzymes, particularly the matrix metalloproteinases, could contribute to PPROM 
risk.  This has been suggested by association studies with promoter variants in the 
MMP1, MMP8, and MMP9 genes (141–143). 
In summary, using a screen to detect deleterious genetic variants that could promote 
PPROM in pregnancies hosted by women of African-American descent, we discovered 
evidence that rare damaging non-sense and frameshift mutations and predicted to be 
damaging missense variants in a variety of genes involved in negatively modulating the 
ECM metabolism-related genes are more prevalent in neonates born from pregnancies 
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complicated by PPROM than normal term pregnancies.  Despite sample size being a 
limitation in our study, the variants identified strongly suggest that the fetal contribution 
to PPROM is polygenic and driven by multiple rare rather than common genetic variants 
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Chapter 5: Expression Patterns of the Chromosome 21 MicroRNA Cluster (miR-
99a, miR-125b and let-7c) in Chorioamniotic Membranes. 
 
Please note: This chapter is accepted for publication in Placenta as  
Bhavi Modi, Sonya Washington, Scott W. Walsh, Colleen Jackson-Cook, Kellie J. 
Archer, Jerome F. Strauss, III. Expression Patterns of the Chromosome 21 MicroRNA 
Cluster (miR-99a, miR-125b and let-7c) in Chorioamniotic Membranes. 
 
 
 
Abstract 
Trisomy 21 (T21) is the most common chromosome abnormality in humans and is 
associated with a spectrum of phenotypes, including cognitive impairment, congenital 
heart defects and immune system defects. In addition, T21 is also associated with 
abnormalities of fetal membranes including chorioamniotic separation, delayed fusion of 
the chorioamniotic membranes, defects in syncytiotrophoblast formation, as well as 
amniocyte senescence. There is evidence indicating miRNAs encoded by sequences 
on chromosome 21 (Chr-21) are involved in several of the cognitive and neurological 
phenotypes of T21, but the role of Chr-21 derived miRNAs in fetal membrane 
abnormalities associated with T21 has not been investigated. In the current study, we 
determined the expression patterns of three miRNAs derived from a cluster on Chr-21 – 
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hsa-miR-99a, hsa-miR-125b and hsa-let-7c in chorioamniotic membranes obtained from 
term pregnancies with spontaneous rupture (n = 20). Tissue and location specific 
expression patterns within the chorioamniotic membranes were identified. The rupture 
zone in the choriodecidua had distinct expression patterns compared to other fetal 
membrane locations.  Despite the increased gene dosage associated with T21, the 
expression of all three miRNAs was reduced in cultured T21 amniocytes as compared 
to cultured euploid amniocytes. In silico analysis of experimentally validated targets of 
the three miRNAs suggest these Chr-21 derived miRNAs play a potential role in fetal 
membrane rupture and the fetal membrane defects associated with T21. 
 
5.1. Introduction  
Trisomy 21 (T21) is associated with abnormalities of the fetal membranes, including 
chorioamniotic separation and delayed fusion of the amnion and chorion (144–146). 
Cytotrophoblast abnormalities and early amniocyte senescence have also been 
reported (147,148). Early senescence of fetal extraembryonic tissues has been 
proposed to contribute to preterm birth (149). The underlying pathophysiological 
explanations for these abnormalities have not been elucidated. Epigenetic alterations in 
the chorion and amnion (differential DNA methylation) have been reported, raising the 
possibility that both chromosome dose, as well as epigenetic factors, contribute to 
dysfunction associated with cells in the fetal membranes (150). 
MicroRNAs (miRNAs) are small (20-24 nucleotides) single-stranded, noncoding, 
regulatory RNA molecules. They are involved in post-transcriptional regulation of gene 
expression either by complimentary binding to the 3’ untranslated region of their target 
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mRNA, thereby inhibiting translation or inducing mRNA degradation (61,62).   Altered 
expression of microRNAs, including those encoded on chromosome 21 (Chr-21), are 
thought to contribute to the phenotypes associated with T21 (151,152). However, the 
role of these miRNAs in the fetal membrane abnormalities associated with T21 has not 
been studied in detail. We examined the pattern of expression of a cluster of Chr-21 
microRNAs that are potential candidates for altering fetal membrane function in T21. 
We determined the relative levels of expression of the 3 microRNAs in this cluster in the 
amnion and choriodecidua, as well as differences in expression in different locations 
within the fetal membranes.  Examination of in vitro cultured amniocytes from normal 
pregnancies and pregnancies hosting a T21 fetus revealed that T21 is associated with 
reduced expression levels of these three microRNAs.  Based on the known roles of 
these microRNAs in the epigenetic control of gene expression, some of the fetal 
membrane structural defects and cellular abnormalities associated with T21 could be 
explained by altered expression of this microRNA cluster.  
 
5.2. Materials and Methods  
5.2.1. Study Population: Self-reported African-American women admitted at MCV 
Hospitals, Richmond, VA, with spontaneous labor at term (defined as more than 37 
weeks of gestation) with rupture of membranes (n = 20) were recruited for the study. 
Women with multiple gestations, fetal anomalies, connective tissue diseases and 
pregnancy complications requiring induction of labor were excluded. Fetal membrane 
specimens were collected as described below from 12 male and 8 female fetal subjects 
delivered from 20 term pregnancies.  
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In order to test the effect of gene dosage on the expression of the Chr-21 localized 
miRNA cluster that were assessed in this study, cultured amniocyte specimens from 
local cell repository of cryopreserved specimens were evaluated from fetuses (race 
unknown) with a T21 complement (n = 7; T21 cases) or a disomic chromosomal 
complement (n = 6; controls).  Fetal sex of the amniocyte cultures were as follows: T21 
cases (2 males, 5 females); euploid controls (4 males, 2 females). 
The study was approved by the Institutional Review Board of MCV Hospitals, 
Richmond, VA. Written informed consent was obtained from the patients before 
collection of samples. 
5.2.2. Collection of samples: Human placentas and fetal membranes were obtained at 
the time of vaginal delivery or when C-section was performed at term. Fetal membranes 
specimens were collected within 1-2 hours of delivery.  After visual identification of the 
rupture zone (Figure 5.1) as done previously by Nhan-Chang et al (153),  the two 
adherent fetal membranes (amnion and choriodecidua) were separated/ teased apart 
from the rupture tear line. A piece of membrane tissue (~ 2cm2) spanning the rupture 
site was dissected sharply from both the amnion as well as the choriodecidua, 
constituting the rupture zone amnion (RZA) and rupture zone choriodecidua (RZC) 
samples, respectively. The two membranes were continuously teased apart and pieces 
of both the amnion and choriodecidua were dissected at the mid region, which was 
halfway between the rupture site and the placenta, followed by at the peri-placental 
region, which is adjacent to the placenta. This method yielded a set of 6 specimens 
from each patient: 1) amnion from the rupture zone (RZA), 2) choriodecidua from the 
rupture zone (RZC) (3) amnion from the mid-region (MRA), 4) choriodecidua from the 
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mid-region (MRC), 5) amnion from the peri-placental region (PPA), 6) choriodecidua 
from the peri-placental region (PPC).  
The amniocytes from T21 cases and euploid controls (defined above) were established 
in culture (monolayer cultures in flasks), propagated in vitro (1 – 3 passages), and 
cryopreserved using standard techniques (154,155). The frozen cell aliquots were 
retrieved and maintained on ice prior to RNA isolation, which was accomplished as 
described below. The amniocyte cultures constitute a mixed population of fibroblast 
cells, amniotic fluid cells (derived from fetal membranes and trophoblasts) and epithelial 
cells (derived from epithelial fetal skin, bladder and other epithelia). The tissue culture 
procedure selects for growth of fibroblast-like cells, followed by amniotic fluid cells and 
epithelial cells with decreasing proliferative capacity in culture respectively (155).  
5.2.3. RNA isolation and miRNA qPCR: For the miRNA-qPCR assays, total RNA was 
extracted using miRVana miRNA isolation kit (Ambion Life Technologies) following the 
manufacturer’s protocol. MicroRNA qPCRs were performed using the TaqMan 
MicroRNA Assays (Life Technologies) following the manufacturer’s instructions. Briefly, 
10ng RNA was reverse transcribed using the target (miRNA) specific stem-loop RT 
primer and the TaqMan MicroRNA reverse transcription kit. The cDNA was then 
amplified by real-time qRT-PCR using target specific TaqMan primer-probe mix. The 
qRT-PCR was performed in triplicates per sample. Different small RNAs (RNU48, 
RNU43 and miR-16) were tested for consistent expression across all samples and 
RNU48 was selected for normalization of the qRT-PCR expression data. The mean 
expression value for each miRNA was divided by the mean RNU48 expression value to 
normalize each sample. 
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5.2.4. Statistical analysis: For miRNA qPCR assays in amniocyte samples from T21 
cases and controls, normalized qPCR expression values for the three miRNAs (hsa-
miR-99a, hsa-miR-125b and hsa-let-7c) were log2 transformed and used for student’s t-
test for determining statistical significance (P < 0.05).   
For miRNA expression analysis in the fetal membranes normalized expression values 
from qPCR for the three miRNAs (hsa-miR-99a, hsa-miR-125b and hsa-let-7c) from the 
6 specimens collected for each of the 20 participating subjects were log2 transformed 
prior to statistical analysis. For each miRNA, a random coefficient mixed effects model 
predicting log2 expression was fit, including the location/tissue factor variable as a fixed 
effect and subject as a random effect (156).  Linear contrasts from the mixed effects 
model were constructed to test the following: MRA versus MRC; PPA versus PPC; RZA 
versus RZC; MRA versus PPA; MRA versus RZA; PPA versus RZA; MRC versus PPC; 
MRC versus RZC; PPC versus RZC; and Amnion versus Choriodecidua.  Adjusted p-
values are reported for the linear contrasts using the single-step method (p < 0.05 was 
considered significant) (157).  
To compare male and female fetal subjects with respect to miRNA log2 qPCR 
expression, Welch’s t-test was performed for each miRNA (let-7c, miR-125b and miR-
99a), location (MR, PP, RZ and VP) and tissue (Amnion, Choriodecidua), adjusting for 
possible unequal variances between the groups. A Bonferroni correction was used to 
control for multiple comparisons and an adjusted alpha level of 0.0071 or below was 
considered significant (157). 
All statistical analyses were performed in the R programming environment (121).  
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5.2.5. MicroRNA target identification and pathway analysis. The miRNA target 
prediction filter in Qiagen’s Ingenuity® Pathway Analysis tool (IPA®, QIAGEN Redwood 
City, www.qiagen.com/ingenuity) was used to identify potential target genes for hsa-
miR-125b, hsa-miR-99a and hsa-let-7c. Pathway analysis was performed in IPA on 
target genes with experimentally observed interactions with the miRNAs.  
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Figure 5.1. Sites of tissue collection 
The placenta with the fetal membranes showing the representative sites of tissue 
collection by region i.e. gross sites for the membrane rupture called the Rupture Zone 
(RZ), Mid-Region (MR) and the Peri-placental (PP) regions.  For RZ, MR and PP 
regions tissues were collected from both the amnion (A) and the choriodecidua (C) 
separately.  
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5.3. Results 
5.3.1. Trisomy impacts expression of the Chr21Orf34 microRNA cluster: The qPCR 
miRNA expression assays that were completed on cultured amniocytes revealed 
significant differences (p < 0.05) in the expression of all three miRNAs between the T21 
cases (n = 7) compared to disomic controls (n = 6), with reduced expression levels in 
T21 amniocytes. For each miRNA, dot-plots of log2 expression (normalized by RNU48) 
by case and control are presented in Figure 5.2.  
5.3.2. Differential miRNA expression patterns are observed between the amnion 
and the choriodecidua and at different locations within the choriodecidua: For 
each miRNA, normalized qPCR expression values for all samples (n = 20) were log2 
transformed for each of the location/ tissue types and used for statistical analysis. Q-
PCR results are shown in Figure 5.3. The differences and adjusted p-values for linear 
contrasts from the random coefficient mixed effects model for all pairwise comparisons 
are reported in Table 5.1 and visually displayed in Figure 5.4. Comparisons between the 
amnion and the choriodecidua at different locations revealed that all three miRNAs had 
significant expression differences at the rupture zone. For the non-rupture sites, for 
miR99a and let-7c there were significant expression differences at the mid-region, 
whereas miR-99a and miR-125b were differentially expressed between the amnion and 
the choriodecidua at the peri-placental region. None of the three miRNAs had significant 
differences at any location within the amnion. Comparatively, the choriodecidua showed 
significant differences (lower abundance) between the rupture zone and non-rupture 
sites, with all three miRNAs showing significant lower abundances between the rupture 
zone and the peri-placental region, and miR-99a and let-7c showing significant 
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differences (lower abundance) between the rupture zone and the mid-region 
choriodecidua as well.  
5.3.3. MiRNA Correlation in amnion and the choriodecidua by location: Pearson’s 
correlation was used to examine the strength of linear relationship (pairwise) between 
the log2 expression of the three miRNAs by location for amnion (Table 5.2) and for the 
choriodecidua (Table 5.3).  All pairwise miRNA relationships in all 3 locations in the 
amnion as well as the choriodecidua were positively correlated, though the strength of 
correlation (determined by ρ) varied with specimen tissue/ site. For the periplacental 
region, all pairwise miRNA comparisons showed significant correlations (P < 0.05) for 
both the amnion and the choriodecidua. Other significant pair-wise correlations in 
expression between miRNAs were observed in the choriodecidua at the mid-region (let-
7c and miR-125b) and at the rupture zone (let-7c and miR-125b, as well as miR-99a 
and miR-125b) with miR-99a and miR-125b showing a strong correlation (ρ > 0.5) at 
this site.  
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                        (Fig. 5.2.A)                                                            (Fig. 5.2.B) 
         
                                                            (Fig. 5.2.C)   
                         
                                     
 
Figure 5.2 MiRNA Expression in Amniocytes  
Significant differences (p < 0.001) in miRNA expression were observed between T21 
case (n = 7) and disomic control (n = 6) amniocyte samples for hsa-miR-let7c (A), hsa-
miR-125b (B) and hsa-miR-99a (C). 
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                         (Fig. 5.3.A)                                                     (Fig. 5.3.B) 
   
 
 
                                                          (Fig. 5.3.C) 
 
                                  
                                                                  
 
Figure 5.3. MiRNA Expression in Fetal Membranes 
qPCR results for log2 expression of hsa-let-7c (A), hsa-miR-125b (B) and hsa-miR-99a 
(C) for each group/site of collection are shown. (PP=Periplacental, MR=MidRegion, 
RZ=Rupture Zone; A = Amnion/C = Choriodecidua). (Sample N = 20). Data are 
represented as Mean ± Standard Error (*P < 0.001, **P = 0.002, ***P<0.05) 
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                         (Fig. 5.4.A)                                                     (Fig. 5.4.B) 
 
 
                                                          (Fig. 5.4.C) 
                                  
 
Figure 5.4. Comparison of miRNA expression by tissue and location. Dot-plot of 
log2 expression for hsa-let7c (A), hsa-miR-125b (B) and hsa-miR-99a (C) are shown for 
each specimen collection location, separated by amnion (left) versus choriodecidua 
(right). Each subject’s observations are connected with a line.  
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Table 5.1. Pairwise comparisons of miRNA expression by tissue and location 
The differences (log2 contrast estimates) and adjusted p-values for linear contrasts from 
the random coefficient mixed effects model for all pairwise comparisons are shown for 
hsa-let7c, hsa-miR-125b and hsa-miR-99a.  (P < 0.05, considered significant, shown in 
bold)  
 
Comparison 
Let-7c Estimate 
(Adjusted p-value) 
miR-125b Estimate 
(Adjusted p-value) 
miR-99a Estimate 
(Adjusted p-value) 
MRA vs. MRC 0.8127 (<0.001) 0.5421 (0.1222) 1.3674 (<0.001) 
PPA vs. PPC 0.8161 (0.0873) 1.0005 (0.0331) 1.3056 (<0.001) 
RZA vs. RZC 1.6851 (<0.001) 1.0628 (<0.001) 1.5455 (<0.001) 
A vs. C 1.1046 (<0.001) 0.8685 (<0.001) 1.4062 (<0.001) 
MRA vs. PPA -0.1980 (0.961) -0.70407 (0.0643) -0.1492 (0.9879) 
MRA vs. RZA 0.2743 (0.287) 0.01895 (1.0000) 0.2807 (0.2066) 
PPA vs. RZA 0.4722 (0.648) 0.72302 (0.3538) 0.4299 (0.5728) 
MRC vs. PPC -0.1945 (0.638) -0.24567 (0.3453) -0.2110 (0.4481) 
MRC vs. RZC 1.1466 (<0.001) 0.53970 (0.0757) 0.4588 (0.0027) 
PPC vs. RZC 1.3412 (<0.001) 0.78537 (0.0024) 0.6698 (<0.001) 
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Table 5.2. Pairwise Pearson’s correlation for log2 miRNA expression by location 
for amnion. The strength of linear relationship (pairwise) between the log2 expression 
of the three miRNAs in the amnion by location is shown. Values represent Pearson’s 
coefficient of correlation (ρ) with estimated p-values in parentheses.  (P < 0.05 
considered significant, shown in bold) 
Comparison 
Periplacental 
ρ (p-value) 
MidRegion 
ρ (p-value) 
Rupture Zone 
ρ (p-value) 
let-7c & miR-99a 0.627 (0.003) 0.255 (0.28) 0.407 (0.07) 
let-7c & miR-125b 0.560 (0.01) 0.209 (0.38) 0.029 (0.90) 
miR-99a & miR-125b 0.541 (0.01) 0.291 (0.21) 0.336 (0.15) 
 
 
Table 5.3. Pairwise Pearson’s correlation for log2 miRNA expression by location 
for the choriodecidua. The strength of linear relationship (pairwise) between the log2 
expression of the three miRNAs in the choriodecidua by location is shown. Values 
represent Pearson’s coefficient of correlation (ρ) with estimated p-values in 
parentheses.  (p < 0.05 considered significant, shown in bold) 
Comparison 
Periplacental 
ρ (p-value) 
MidRegion 
ρ (p-value) 
Rupture Zone 
ρ (p-value) 
let-7c & miR-99a 0.469 (0.04) 0.445 (0.05) 0.383 (0.10) 
let-7c & miR-125b 0.514 (0.02) 0.495 (0.03) 0.453 (0.04) 
miR-99a & miR-125b 0.665 (0.001) 0.362 (0.12) 0.646 (0.002) 
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5.3.4. Pathway analysis of genes targeted by miRNAs: MicroRNA target prediction 
filter in IPA identified a total of 217 experimentally observed miRNA-target gene 
interactions for all three miRNAs. The 212 target genes from these interactions were 
used for core pathway analysis in IPA to identify pathways, diseases & bio-functions 
and networks that are “over-represented” in target genes of the Chr-21 microRNA 
cluster. The key findings from the pathway analysis are shown in Table 5.4. Of note, 
several of the functional annotations suggest involvement of cell survival, cell death and 
cellular development pathways (molecular mechanisms of cancer), which play a role in 
fetal membrane rupture. In addition, a significant number of targeted genes overlap with 
the categories of reproductive system disease (101 genes) and developmental disorder 
(45 genes), which also have a strong association with preterm birth, as well as T21. The 
top network (Figure 5.5), based on the functional annotations of the target genes, had 
26 focus molecules (26 of the 212 target genes) and IPA Network Score = 48. The 
associated network functions involving the cell cycle, connective tissue development 
and function, and cancer. All of these functions have been shown to have strong 
correlations with membrane rupture and/ or phenotypic traits associated with Down’s 
syndrome.   
5.3.5. Fetal gender and miRNA expression: Fetal gender is known to be associated 
with adverse pregnancy outcomes (158,159). Male (n = 12) and female (n = 8) fetal 
subjects in the study were compared with respect to miRNA expression (log2 qPCR 
estimates) for each miRNA for each of the 6 groups or sampling sites. Only let-7c in 
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mid-region choriodecidua samples was significantly different (p < 0.0071) when 
comparing fetal gender. (Appendix, Tables A.5.1 – A.5.3)  
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Table 5.4. Ingenuity pathway analysis of the genes targeted by hsa-miR-99a, hsa-
miR-125b and hsa-let-7c.  Key findings from the pathway analysis (performed in IPA) 
of the 212 genes targeted by the three miRNAs in the Chr21 cluster are described. The 
Top Canonical Pathways (5.4.A), Top Diseases and Disorders (5.4.B), Top Molecular 
and Cellular Functions (5.4.C) and Physiological System Development and Functions 
(5.4.D) over-represented in the target genes are shown. 
5.4.A: Top Canonical Pathways  
Name p-value Overlap 
Bladder Cancer Signaling  1.04E-09 12.60% 
Chronic Myeloid Leukemia Signaling  5.26E-10 11.50% 
Glioblastoma Multiforme signaling 4.18E-13 10.70% 
Colorectal Cancer Metastasis Signaling  3.80E-09 6.50% 
Molecular Mechanisms of Cancer 3.61E-12 6.10% 
 
5.4.B: Top Diseases and Disorders 
Name  p-value No. of gene 
Organismal Injury and Abnormalities 3.7E-07 - 3.82E-18 153 
Cancer 3.7E-07 - 3.82E-18 151 
Reproductive System Disease 3.7E-07 - 5.73E-15 101 
Tumor Morphology 2.02E-07 - 3.85E-17 51 
Developmental Disorder 3.68E-07 - 2.88E-14 45 
 
5.4.C: Top Molecular and Cellular Functions 
Name  p-value No. of genes 
Cellular Growth and Proliferation  3.70E-07 - 1.34E-20 125 
Cellular Development 3.70E-07 - 1.34E-20 112 
Cell Death and Survival 3.32E-07 - 5.40E-18 110 
Cellular Movement  3.10E-07 - 3.43E-13 70 
Cell Cycle 3.70E-07 - 2.93E-16 64 
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5.4.D: Physiological System Development and Function 
Name  p-value 
No. of 
genes 
Organismal Development 3.31E-07 - 1.03E-17 115 
Organismal Survival 5.59E-15 - 3.97E-18 90 
Tissue Morphology 1.22E-07 - 4.65E-14 78 
Hematological System Development and Function 3.21E-07 - 6.85E-14 67 
Lymphoid Tissue Structure and Development  3.21E-07 - 2.97E-14 62 
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Figure 5.5. IPA network. The	 top	 IPA	 network	 (Score	 =	 48)	 with	 26	 of	 the	 212	experimentally	observed	target	genes	of	the	3	miRNAs.	The	associated	network	functions	are	cell	cycle,	connective	tissue	development	and	function	and	cancer.			
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5.4. Discussion 
Increasing numbers of investigators are identifying miRNAs to be involved in 
pathologies of several diseases and disorders, including the features of T21 
(151,152,160,161). Expression patterns of miRNAs have been studied in the placenta 
as well as the chorioamniotic membranes and associations with human pregnancy, 
gestational age, and parturition and pregnancy complications (such as preeclampsia 
and preterm labor) have been found (65,162–164). MicroRNAs are key regulators of 
extracellular matrix (ECM) gene expression and homeostasis, which is perturbed in 
preterm premature rupture of membranes (PPROM). Interestingly, the relationship 
between miRNAs and ECM is thought to be bi-directional with studies suggesting that 
not only can miRNAs regulate ECM composition, but the ECM can also affect miRNA 
expression and function (165). 
Despite the presence of three chromosomes 21 (a trisomic imbalance), the T21 
amniocyte specimens showed reduced expression of the microRNA cluster.  This has 
been observed by others who quantitated expression of the same microRNAs in other 
tissue types and found reduced expression in T21 (152,160).  However, other studies 
have documented increased expression of these miRNAs in T21 as compared to 
euploid controls (151,161,166). These apparent discrepancies could be attributed to 
differences in the tissue specimens investigated or differences in normalization 
techniques. Reduced expression of the microRNAs in the face of increased gene 
dosage may reflect epigenetic changes such as DNA methylation that dampen 
expression (167).  The reduced expression of the three microRNAs would presumably 
increase the expression of the proteins encoded by the target mRNAs. Although all 
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three miRNAs are known to be expressed in the placenta and chorioamniotic 
membranes, an in-depth expression analysis has not been performed. Prior studies 
investigating the roles of these miRNAs in context of other diseases reveal findings 
suggesting a true potential for their involvement in fetal membrane pathology. For 
example, miR-99a expression has been studied in several cancers and plays crucial 
roles in the PI3K/AKT and NF-κB signaling pathways (168,169). In fact, the miR-99a/let-
7c/miR-125b locus on Chr-21 is phylogenetically conserved, is transcribed as a 
polycistronic message, and regulates TGFβ/Wnt signaling pathways in hematopoietic 
stem and progenitor cell homeostasis (170). Members of the miR-125 family of miRNAs 
are involved in diverse cell functions and have been associated with several diseases. 
MiR-125 miRNAs target a range of genes, including transcription factors and matrix 
metalloproteinases (MMPs), which are involved in ECM metabolism and also have 
important functions in immunological pathways. Another study found that miR-125b is 
upregulated in third trimester placentas compared to first trimester placentas, 
suggesting it has a role in gestational age (162,171).  Let-7 miRNAs are negatively 
regulated by the RNA-binding protein, Lin28, and both act downstream of the NF-κB 
signaling pathways. Like miR-125b, let-7 miRNAs, including let-7c are upregulated in 
third trimester human placentas compared to the first trimester (162). In support of our 
results, another study found tissue-specific let-7c expression differences at term, with 
significantly reduced expression in choriodecidua as compared to amnion and placenta 
(172).  
In the current study, in addition to the tissue-specific expression patterns, we also show 
differential expression patterns at different locations within the choriodecidua. 
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Differences between the rupture zone and the non-rupture sites are especially 
biologically relevant. The rupture site of fetal membranes is characterized by unique 
histologic and biochemical changes. These changes are observed even in the portion of 
fetal membranes overlying the cervix (thought to be eventual site of spontaneous 
rupture) in patients at term without labor. This area is termed as the “zone of altered 
morphology” (ZAM) and is characterized by increased thickness of connective tissue 
and decreased thickness of cytotrophoblast and decidua (130,173–175). These 
changes would require large-scale transcriptional reprogramming, which can be carried 
out, at least in part, by miRNA-regulation. Nhan-Chang et al (153) showed gene 
expression differences between the amnion and the choriodecidua at both the rupture 
as well as non-rupture sites, whereas within each fetal membrane individually, only the 
choriodecidua showed gene expression differences between the rupture and non-
rupture sites. These results are in accordance with the miRNA expression patterns in 
our study, and support the concept that the altered gene expression in fetal membranes 
in the rupture zone could be due to altered miRNA expression patterns.  It is important 
to note that the decreased thickness in the cytotrophoblast and maternal decidual cell 
layers at the rupture site in the chorion compared to non-rupture sites (130,173–175) 
can influence the observed miRNA expression levels at these sites. Furthermore, the 
genes identified by Nhang-Chang et al (such as IL-6, IL1RN, CXCL12, ADAMTS5) were 
involved in inflammatory response, immune tolerance pathways as well as ECM-
receptor interactions. This suggests that miRNAs from the Chr21orf34 locus could be 
involved in regulation of these pathways in the fetal membranes as well, which is quite 
plausible considering the evidence for these functional roles is already established in 
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other tissues and disease states (165,168–171). In silico pathway analysis of the 
experimentally observed gene targets of the three miRNAs revealed an over-
representation of genes related to cellular growth and proliferation, cell death and cell 
survival pathways, all of which are crucial in ECM function during membrane rupture 
(176). Notably, the top network based on functional annotation of the genes targeted by 
the three miRNAs included COL1A2, which is one of the major fibrillar collagens present 
in fetal membranes contributing to the tensile strength of the amnion and associated 
with preterm birth (105). The network also included SMAD which suggests involvement 
of the TGFβ-Smad signaling pathway which plays a role in ECM metabolism and fetal 
membrane rupture via transcription regulation of various collagens, MMPs and tissue 
inhibitors of metalloproteinases (TIMPs) (48,177). 
In conclusion, we show evidence for distinct tissue and region specific miRNA 
expression patterns in fetal membranes from subjects with spontaneous term labor. 
These miRNAs are expressed at a reduced level in T21 and this alteration may promote 
abnormalities in fetal membranes associated with T21, including chorio-amnion 
separation or delayed fusion of the chorion and amnion.  
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Chapter 6: Perspectives and Future Directions 
 
 
 
Please note:  
The section “6.2.1: A hypothetical model for DENND1A and GWAS candidate loci in 
PCOS” is adapted from a published journal article 
(Jan M. McAllister, Richard S. Legro, Bhavi P. Modi, and Jerome F. Strauss III. 
Functional genomics of PCOS: from GWAS to molecular mechanisms. Trends in 
Endocrinol Metab, 2015; 26 (3)) 
The section “6.2.3: Pharmacogenomics in PCOS” is part of a published journal article 
(Cindy T. Pau*, Kai I. Cheang*, Bhavi P. Modi, Thushiga Kasippillai, Candace C. 
Keefe, Maria Shulleeta, William S. Evans, Lubna Pal, Jerome F. Strauss III, John E. 
Nestler, Corrine K Welt. The Role of Variants Regulating Metformin Transport and 
Action in Women with Polycystic Ovary Syndrome. (*Authors contributed equally); 
Pharmacogenomics 2016; 17 (16)) 
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6.1. Underlying themes  
While all of the projects described in this thesis are more or less distinct, they all are 
focused on understanding the genetic and epigenetic differences leading to disease 
susceptibility. Each chapter employs a unique data set with the most relevant 
approaches used to answer specific questions. Beyond the specific research questions 
addressed in each chapter, certain wider themes were apparent across multiple 
projects, which pertain to the study of complex genetic studies as a whole. Central to 
the study of complex genetic traits is the understanding of gene expression regulation 
and function. This is a multistep process that includes defining the genetic architecture, 
identifying genes and variants within these genes associated with disease risk and 
translating these associations into disease mechanisms. As explained in the 
introduction, the chapters in this thesis take different approaches towards reaching this 
goal in the context of two complex reproductive disorders – PCOS and PPROM. 
Chapter 2 describes the investigation of different possible genetic mechanisms for V2 
overexpression in PCOS and the negative results obtained indicate either we do not 
have sufficient data to clearly elucidate a genetic mechanism (owing to small sample 
size) or that epigenetic mechanisms may play a role and the results in Chapter 3 
support our hypothesis by showing evidence for potential miRNA regulation of the 
DENND1A gene. In addition, it is important to note other epigenetic mechanisms 
including DNA methylation and histone modifications may be involved and need to be 
studied. In addition, Chapter 4 describes an approach to identify low frequency rare 
variants that contribute to PPROM risk susceptibility in select candidate genes by 
integrating bioinformatics and known disease pathology (discussed below).    
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One additional theme is the role of miRNAs contributing to the epigenetic mechanisms 
of complex disorders as discussed in Chapters 3 and 5. While DNA methylation and 
histone modifications are usually investigated in lieu of epigenetic regulation of gene 
expression, miRNAs also contribute to this landscape of gene expression regulation by 
post-transcriptional translational inhibition or mRNA degradation with no changes to the 
underlying DNA sequence. Differential miRNA expression patterns have contributed to 
several disease mechanisms including cancer, neurological disorders, cardiovascular 
diseases, diabetes etc. Chapter 3 shows evidence for differential expression for two 
different miRNAs in PCOS theca cells. In addition, differential expression was correlated 
to increased androgen (DHEA) production – which is a measure of the 
hyperandrogenism associated with PCOS. In addition, Chapter 5 describes tissue and 
location specific expression patterns of Chr-21 derived miRNAs in the chorioamniotic 
membranes in term pregnancies with spontaneous rupture. The results suggest a 
unique expression pattern in rupture site of the chorion, supporting our hypothesis that 
gene expression changes at the rupture site leading to membrane rupture at term could 
be regulated by miRNAs. This pilot study provides support for a detailed miRNA 
expression analysis in fetal membranes from term pregnancies with and without 
membrane rupture and pregnancies complicated by PPROM.  
In addition, utilization of in silico network analysis in Chapters 3 and 5 really underlines 
the overall scope of this thesis by giving preliminary evidence for a common network of 
miRNAs (epigenetic) and genes (genetic) implicated either a priori (by association 
studies) or via validated and/ or predicted miRNA-gene interactions being involved in 
complex disease susceptibility.   
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Another common theme is integration of biological theory and standard next-generation 
genetic analysis techniques to make the studies more functionally informative. 
Identification of risk loci will have applicable value only when risk loci can improve our 
understanding of disease pathophysiology and in the long-term impact healthcare 
management and a “hypothesis-driven” approach can aid in designing studies that are 
better equipped in this direction. This was particularly helpful in Chapter 4 where 
knowledge of biological function of genes and association to biological etiology of 
disease allowed us to focus on a manageable number of candidate genes and variants 
there in from a large data set obtained from Whole Exome Sequencing. In addition, prior 
studies on biological relevance of DENND1A in PCOS directed the mechanistic and 
functional aspects of Chapters 2 and 3. Moreover, Chapter 5 integrates epidemiological 
evidence of fetal membrane abnormalities in Trisomy 21 and contribution of Chr-21 
miRNAs to T21 phenotypes leading to the study of location and tissue specific 
expression patterns of Chr-21 miRNAs in chorioamniotic membranes. 
The results obtained in each separate project reinforce the notion that both genetic and 
epigenetic mechanisms and their complex interactions need to be studied in detail to 
understand the complex traits. As discussed in the introduction, several of these 
mechanisms are even more challenging to study for complex reproductive traits and 
adverse pregnancy outcomes such as PCOS and PPROM respectively. This thesis is 
an example of how a better understanding of these concepts can be achieved by 
defining specific research questions and identifying the best methods to address those 
questions effectively. In addition, several of these studies have led to potential future 
directions that will add more clarity towards the genetic and epigenetic mechanisms in 
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complex reproductive disorders. The rest of the chapter entails brief descriptions of 
these future projects some of which are already in progress.  
 
6.2 Future Directions 
6.2.1. A hypothetical model for DENND1A and other GWAS candidate loci in 
PCOS 
A previous study has described the role of increased expression of a DENND1A isoform 
- V2 contributing to PCOS pathophysiology via steroidogenic regulation in PCOS theca 
cells (70), however the precise etiology by which V2 alters theca cell function is not 
known. However, the structural features of the V2 protein and its cytoplasmic and 
nuclear location in theca cells described previously (70) provide important clues for 
speculating a possible molecular model for its function, perhaps in conjunction with 
other GWAS candidate loci (Figure 6.1.). V2 could be involved in modification of 
gonadotropins (FSHR, LHCGR) and INSR (all three are known GWAS candidate loci) 
signal transduction cascades via receptor-mediated recycling/ endocytosis through 
clathrin-coated vesicles by interactions via the clathrin-binding domain in the V2 
structure. In addition, DENND1A functions as a Rab-specific guanine nucleotide 
exchange factor (GEF) that interacts with Rab-specific GTPases such as RAB5B (also a 
GWAS candidate gene) and are involved in endocytic processes. V2 could influence 
gene transcription of androgen producing genes by transport of ligand (FSH, LH, INS) 
and/ or receptor (FHSR, LHCGR, INSR) into the nucleus via these processes. 
Alternatively, V2 localized in the nucleus could be a scaffold for transcription factors 
some of which are GWAS genes including TOX3, YAP1, HMGA2 and ZNF217 or others 
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such as GATA family of transcription factors which ultimately regulate steroidogenic 
enzyme gene expression. These transcription factors can act independently of V2 to 
influence gene expression as well. Preliminary evidence (not shown) indicates V2-
mediated activation and regulation of PI3K/MAPK pathways, which could then regulate 
several other downstream signaling cascades leading to transcriptional regulation of 
gene expression contributing to the PCOS phenotype. Detailed molecular studies 
designed to clearly define and outline these hypothesized interactions need to be 
performed.  
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Figure. 6.1. A hypothetical model for DENND1A and other GWAS candidate loci in 
PCOS. The different possible mechanisms by which DENND1A and other GWAS 
candidate loci (shown in brown boxes) can contribute to the steroidogenic phenotype of 
PCOS theca cells is shown. The different mechanisms (described in detail in section 
6.2.1) include gene transcription regulation via DENND1A mediated endocytosis of 
ligand/ receptor via clathrin-coated vesicles without or in conjunction with RAB5B and 
gene expression regulation via transcription factors dependent or independent of 
nuclear V2.  
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6.2.2. A transgenic mouse model for PCOS  
 
The existing PCOS animal models are based on treatment of the animals with 
androgens, or prenatal exposure to androgens in utero (178,179). However, a mouse 
model created following a gene-based approach is lacking. Based on our studies with 
DENND1A in theca cells (70), it was hypothesized that global overexpression of human 
DENND1A.V2 in a transgenic mouse should reproduce the PCOS phenotype (at least 
the steroidogenic phenotype). In addition, this provides an opportunity to study the 
pathophysiological role of V2 in PCOS in vivo. A C57BL6 background was used to 
create three transgenic lines overexpressing V2 using the construct shown in Figure 
6.2.  
While transgene expression at the mRNA level was detectable in two of the three 
transgenic lines, establishing transgene protein expression was inconsistent and 
difficult. Fertility and fecundity did not appear to be different between wildtype (WT) and 
transgenic (Tg) animals. Steroidogenic phenotypes of increased plasma DHEA, 
androstenedione, progesterone and testorone levels were observed in Tg animals 
compared to WT. Unlike humans, mouse adrenal glands do not synthesize androgen 
(180). However, Cyp17 gene expression (mRNA and protein) was detected in the 
adrenal glands of Tg animals overexpressing V2, whereas, no expression was detected 
in the WT animals. Adrenal androgen production needs to be further confirmed by 
cortisol assays.  
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Figure 6.2. DENND1A.V2 construct. pCMV-BAM vector containing the human 
DENND1A.V2 cDNA under control of the CMV promoter, as well as rabbit β-globin 
sequences that provide an intron for efficient transgene expression and a 
polyadynelation site. This construct was used to create three transgenic lines on a 
C57BL/6 background.    
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6.2.2. Rare variant analysis in negative regulators of the immune response 
contributing to PPROM.   
As described in Chapter 4, identification of low-frequency rare variants in the fetal 
genome is an approach towards identification of genetic variants contributing to disease 
susceptibility in PPROM that has not been used. As Chapter 4 focused on damaging 
variants in fibrillar collagen genes contributing to ECM structure and metabolism, using 
a similar approach, future studies will focus on identification of rare variants in fetal 
genes involved in the suppression of the inflammatory response triggering matrix 
degradation.  
Chorioamnionitis (inflammation of fetal membranes) and/ or unchecked innate immune 
response resulting from bacterial infection are major risk factors associated to PPROM 
(181–183). Gene expression differences of key mediators of inflammation and innate 
immune response pathways in fetal membranes of normal term pregnancies and 
PPROM patients have been identified. Negative regulators on innate immune signaling 
help to keep inflammation in check. Host genetic factors significantly contribute to inter-
individual variation in susceptibility to infection and severity on innate immune response. 
Identification of damaging variants that potentially disrupt expression and/ or function of 
genes involved in negative regulation of inflammation and the innate immune response 
may lead to identification of genetic predictors of PPROM. Using this rational and the 
same methodology described in Chapter 4, the candidate genes interrogated included 
anti-inflammatory cytokines such (IL10, IL10RA, IL10RB), suppressors of cytokine 
signaling (SOCS1, SOCS2, SOCS3), intracellular mediators (CARD6, CARD8, NOD2, 
NFKBIE) and pattern recognition receptors (NLRP3, NLRP10, NLRP12, TLR10).  
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Of particular note were the mutations/potentially damaging variants in NFKBIE, an 
inhibitor of the NFkB activation (Appendix Table A.6.1). In addition, predicted to be 
damaging missense variants were found only in PPROM cases in NLRP10, a negative 
regulator of the innate immune inflammasome pathway and NOD2, an intracellular 
protein in the NFkB pathway. A frameshift mutation rs2066847 was identified in the 
NOD2 gene with allele frequency of 0.0042 in all PPROM cases combined (49 cases 
used in WES and 188 cases used for the follow-up genotyping). A nonsense mutation, 
rs765522475, was identified in the NLRP10 gene with an allele frequency of 0.0021 in 
all PPROM cases combined. Detailed analysis of these variants in association to 
PPROM is warranted. 
6.2.3. Pharmacogenomics in PCOS 
As mentioned earlier, true value of identification of genetic variants impacting disease 
susceptibility lies in their applications towards understanding disease pathophysiology 
and contribution towards healthcare. Pharmacogenomics, which is the study of how 
genes and genetic variants affect a person’s response to drugs, is now being 
increasingly applied to the study of complex genetic disorders as well. In an attempt to 
study the application of pharmacogenomics in PCOS, a small project to understand the 
role of variants regulating metformin transport and action in women with Polycystic 
Ovary Syndrome was performed. The study was a collaborative effort and has been 
published in Pharmacogenomics (184). A brief description of study design and key 
findings for the work performed at Virginia Commonwealth University are described 
below.  
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Metformin is widely used to treat women with PCOS based on the concept that it 
improves insulin resistance. However, reports have demonstrated that metformin does 
not improve insulin resistance, rather it improves fasting glucose levels and glucose 
effectiveness in women with PCOS. In addition, other reports indicate that metformin 
lowers testosterone levels and increases ovulation rates in a subset of women with 
PCOS independent of insulin action (185–189). Thus, the mechanism of metformin 
action in PCOS remains unclear and identifying the subset of patients who will benefit 
from metformin remains a challenge. Metformin is transported into hepatocytes by 
organic cation transporter 1 (OCT1 or SLC22A1), out of hepatocytes and renal tubular 
epithelium by multidrug and toxin extrusion 1 (MATE1 or SLC47A1), and eliminated 
through the renal tubule cells by organic cation transporter 2 (OCT2 or SLC22A2). All 
three transporters are expressed in the ovaries, hepatocytes and skeletal muscle and 
genetic variants in these genes have been demonstrated to affect metformin transport 
response in patients with type 2 diabetes. In addition to metformin transport protein 
heterogeneity, a variant in linkage disequilibrium with the ataxia-telangiectasia mutated 
gene (ATM; rs11212617) has been associated with reduced HbA1C levels after 
metformin treatment through phosphorylation and activation of the AMPK pathway 
(190–194). This suggested that the genetic variability in metformin transporters and 
mediators may affect metformin levels and action in relevant tissues in women with 
PCOS and have clinical significance.  
Genotyping for loss of function variants (associated with protein change) in SLC22A1, 
SLC22A2, SLC47A1 and ATM was performed on genomic DNA isolated from women 
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with PCOS (n = 26). (Details regarding the other cohorts, clinical criteria and metformin 
dosage used can be found in the full version of the paper (184)).  
Briefly, the study failed to demonstrate a relationship between metformin transporter 
variants and glucose, insulin and testosterone levels, a response to an oral glucose 
tolerance test, and ovulation in patients with PCOS. Thus, the data from the current 
study does not support an important effect of these variants in the response to 
metformin in PCOS.  
However, it is important to note the heterogeneity in the different sample cohorts used in 
the study – including the strength and duration of metformin treatment, which can mask 
true effects. This highlights the need for replication studies with increased sample sizes 
and uniform study design.  
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Table A.3.1.  Specific theca cell cultures used for miRNA sequencing and qPCR 
assays in Chapter 3 (miRNA and gene qPCRs). C and F indicate control 
(untreated) and forskolin treated samples  
Sample ID Category 
Included in 
MiRNA 
Sequencing 
Included in 
QPCR assays 
MC02_C/F Normal Yes No 
MC06_C/F Normal Yes Yes 
MC31_C/F Normal Yes Yes 
MC38_C/F Normal No Yes 
MC40_C/F Normal Yes Yes 
MC50_C/F Normal Yes Yes 
MC10_C/F PCOS Yes Yes 
MC16_C/F PCOS Yes Yes 
MC27_C/F PCOS Yes Yes 
MC190_C/F PCOS Yes Yes 
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Figure. A.4.1. COL2A1 mRNA expression in amnion samples from normal term 
pregnancies. 
RT-PCR gel picture for COL2A1 (1371 bp) using 1 µg RNA from amnion tissue samples 
obtained from normal term pregnancies (lanes 1-6) showing mRNA expression of the 
COL2A1 gene in the amnion.  
(COL2A1 Primers: 5-CAAGGCCCCAGAGGTGACA-3 and  
5-AGGCGGACATGTCGATGCCA-3) 
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Table A.4.1.A. Comparison of neonatal ancestry between cases and controls in 
the initial WES:  
Neonatal case (n = 49) and control (n = 20) samples were compared for European and 
West-African ancestry proportions. Values represent mean genetic ancestry estimates 
generated using two-way model of admixture following maximum likelihood method with 
SD in parentheses.  
Ancestry 
Cases 
Mean (SD) 
Control 
Mean (SD) 
p-value 
European 0.295 (0.070) 0.314 (0.107) 0.463 
West-African 0.705 (0.070) 0.685  (0.107) 0.463 
 
Table A.4.1.B Comparison of neonatal ancestry between cases and controls in the 
follow-up genotyping study. 
Neonatal case (n = 188) and control (n = 175) samples were compared for European 
and West-African ancestry proportions. Values represent mean genetic ancestry 
estimates generated using two-way model of admixture following maximum likelihood 
method with SD in parentheses.  
Ancestry 
Cases 
Mean (SD) 
Control 
Mean (SD) 
p-value 
European 0.1823 (0.083) 
 
0.1658  (0.119) 0.134 
West-African 0.8176  (0.083)  0.8341 (0.119) 0.134 
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Table A.4.2. Missense variants not selected. 
Missense variants identified by WES in the genes of interest but not selected for 
analysis in this study are listed along with their SIFT and Polyphen2 predictions and the 
observed putative risk allele frequencies (RAF) for cases (n = 49) and controls (n = 20). 
Novel variants were submitted to dbSNP and ss ids are provided. In cases of multiple 
SIFT and PolyPhen2 predictions for variants that were annotated to multiple isoforms, 
only distinct predictions are listed (i.e. does not reflect the total number of isoforms that 
were actually annotated). (SIFT predictions: T = Tolerated, D = Damaging; Polyphen2 
predictions: B = Benign, P = Possibly Damaging, D = Probably Damaging). 
Gene SNP ID Location 
Allele 
Change 
SIFT 
prediction 
PolyPhen
2_HDIV 
prediction 
RAF 
Cases 
RAF 
Controls 
COL1A1 rs142570406 
chr17: 
48264244 
G > C T B 0.01 0 
COL1A1 rs116794104 
chr17: 
48272827 
C > T T B 0.01 0.025 
COL1A1 rs1800215 
chr17: 
48265495 
T > C T B 0.93 1 
COL1A1 rs145446512 
chr17: 
48266851 
C > T T B 0 0.025 
COL1A2 
ss20194925
54 
chr7: 
94029523 
C > T T P,P 0 0.025 
COL1A2 rs42524 chr7: C > G T B 0.91 0.85 
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94043239 
COL1A2 rs150124840 
chr7: 
94057691 
C > T T P 0.01 0 
COL1A2 rs35820023 
chr7: 
94056353 
G > A T P 0 0.025 
COL2A1 rs140368756 
chr12: 
48372444 
G > A T B,B 0 0.025 
COL2A1 rs3803183 
chr12: 
48398080 
T > A T B,B 0.56 0.575 
COL2A1 rs34392760 
chr12: 
48391657 
T > A T B,B 0.01 0.025 
COL2A1 rs12721427 
chr12: 
48368541 
C > T T B,B 0.03 0 
COL2A1 rs2070739 
chr12: 
48367976 
C > T T D,D 0.05 0.075 
COL2A1 rs201823490 
chr12: 
48380213 
G > A T B,B 0.03 0 
COL3A1 rs201220788 
chr2: 
189870163 
G > A T D 0 0.025 
COL3A1 rs373838193 
chr2: 
189862102 
C > T T D 1 0 
COL3A1 rs1800255 
chr2: 
189864080 
G > A T B 0.1 0.1 
	 157	
COL3A1 rs1801183 
chr2: 
189863424 
C > T T P 0.01 0 
COL3A1 rs41263775 
chr2: 
189864044 
C > G T B 0.01 0 
COL3A1 rs1516446 
chr2: 
189875421 
T > G T B 1 1 
COL5A1 rs147008954 
chr9: 
137593122 
C > G D P 0.01 0 
COL5A1 
ss20194925
56 
chr9: 
137698068 
G > A T D 0 0.025 
COL5A1 rs61729495 
chr9: 
137734039 
G > A T B 0.01 0 
COL5A1 rs61735045 
chr9: 
137642654 
G > A T D 0.01 0 
COL5A1 
ss20194925
55 
chr9: 
137620639 
A > T T B 0 0.025 
COL5A2 rs35852101 
chr2: 
189931144 
A > G N/A B,P 0.01 0 
COL5A2 rs6434313 
chr2: 
189916110 
C > G N/A B 0.01 0.025 
CRTAP rs145623565 
chr3: 
33161975 
A > C T,T P 0.01 0 
CRTAP ss20194925 chr3: G > C T D 0.01 0 
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50 33155942 
ELN 
ss20194925
53 
chr7: 
73474329 
G > T T B 0.01 0 
ELN rs2071307 
chr7: 
73470714 
G > A T B 0.21 0.25 
ELN rs61734581 
chr7: 
73459575 
G > T T D 0.02 0.05 
ELN rs144026807 
chr7: 
73474485 
C > T T B 0.01 0 
ELN rs137987089 
chr7: 
73474484 
G > T T P 0.01 0 
ELN rs140425210 
chr7: 
73477524 
G > A T D 0.01 0.025 
ELN 
ss20194925
52 
chr7: 
73457326 
G > A T D,P 0.01 0 
ELN rs145612009 
chr7: 
73462008 
G > T T D 0.01 0 
ELN rs34945509 
chr7: 
73472000 
A > G T P 0 0.05 
ELN rs144341345 
chr7: 
73470729 
C > G T P 0.03 0.025 
ADAMTS
2 
rs35445112 
chr5: 
178555097 
C > T T B 0 0.05 
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ADAMTS
2 
rs398829 
chr5: 
178634672 
C > T T B 0.43 0.525 
ADAMTS
2 
rs59567206 
chr5: 
178634704 
T > C T B 0.08 0.075 
ADAMTS
2 
rs11750821 
chr5: 
178634683 
C > T T B 0.01 0.075 
ADAMTS
2 
rs143764421 
chr5: 
178634657 
C > T T B 0 0.025 
ADAMTS
2 
rs35372714 
chr5: 
178563002 
C > T T B 0 0.025 
ADAMTS
2 
rs1054480 
chr5: 
178540975 
G > A T P 0.07 0.1 
ADAMTS
2 
rs79330641 
chr5: 
178549719 
G > A T B 0.02 0.05 
ADAMTS
2 
ss20194925
51 
chr5: 
178771124 
C > T T D,P 0.01 0 
SERPIN
H1 
ss20194925
57 
chr11: 
75277973 
G > C T P 0 0.025 
SERPIN
H1 
rs141721173 
chr11: 
75277974 
C > A T B 0 0.025 
SERPIN
H1 
rs138784081 
chr11: 
75277959 
A > G D B,P 0.01 0 
FKBP10 rs34764749 chr17: A > G T B 0.12 0.1 
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39974642 
FKBP10 rs76022961 
chr17: 
39978052 
G > A T P,B 0.02 0.05 
FKBP10 rs201944190 
chr17: 
39978604 
G > A D B 0.01 0 
FKBP10 rs145424241 
chr17:3996
9495 
A > G T D 0.01 0 
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Table A.5.1. Fetal gender comparison for hsa-let-7c. 
Comparisons of log2 expression of hsa-let-7c at the 6 different sampling sites with 
respect to male vs. female fetal gender are shown. (P < 0.0071 was considered 
significant (bold)). 
Location/Tissue mean Female mean Male p-value 
MRA 1.490 0.622 0.12032 
MRC 0.857 -0.310 0.00095 
PPA 1.443 0.983 0.57719 
PPC 0.614 0.176 0.36579 
RZA 1.178 0.373 0.15320 
RZC -0.273 -1.468 0.09397 
 
Table A.5.2. Fetal gender comparison for hsa-miR-125b. 
Comparisons of log2 expression of hsa-let-7c at the 6 different sampling sites with 
respect to male vs. female fetal gender are shown. (P < 0.0071 was considered 
significant (bold)). 
Location/Tissue mean Female mean Male p-value 
MRA -6.212 -6.202 0.991 
MRC -6.137 -6.624 0.483 
PPA -5.401 -5.667 0.777 
PPC -6.408 -6.184 0.624 
RZA -6.583 -5.859 0.502 
RZC -7.179 -7.056 0.870 
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Table A.5.3. Fetal gender comparison for hsa-miR-99a. 
Comparisons of log2 expression of hsa-let-7c at the 6 different sampling sites with 
respect to male vs. female fetal gender are shown. (P < 0.0071 was considered 
significant (bold)). 
Location/Tissue mean Female mean Male p-value 
MRA 1.689 1.323 0.579 
MRC 0.351 -0.015 0.291 
PPA 1.712 1.514 0.706 
PPC 0.165 0.154 0.970 
RZA 1.221 1.369 0.824 
RZC -0.397 -0.483 0.792 
 
 
  
 
 
 
	 163	
Table A.6.1. NFKBIE variants identified in WES and unique to cases.  
 
SNP 
 
Chromosome 6 
Location 
 
Type 
Reference 
Allele 
Alternate 
Allele 
Alternate 
allele 
frequency 
rs10081001 44227330 Intron G A 0.09 
rs12211448 44227751 Intron C A 0.04 
rs2233429 44233488 missense T A 0.01 
rs2233437 44228162 Intron G A 0.17 
rs28362860 44227224 Intron C T 0.04 
rs369182955 44232670 Intron G A 0.01 
rs372668192 44232707 Intron C T 0.01 
rs79985077 44230663 Intron C T 0.01 
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